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Den mätta dagen den är aldrig störst. Den bästa dagen är en dag av törst. Nog finns det mål 
och mening med vår färd – men det är vägen, som är mödan värd – Karin Boye  
     
Till min familj och vänner 
  
ABSTRACT 
Breast cancer is the most common malignancy in women around the world. There have been 
great improvements in treating the disease and today between 80-90% of the women survive 
at least 5-years after their primary diagnosis. Still, due to the high incidence of the disease 
more than 450.000 women die of breast cancer each year worldwide. Much of the 
improvements in breast cancer survival can be explained by better knowledge of the 
development and progression of the disease, hence the treatments have become more 
effective. Yet, we still cannot explain why one patient relapses and dies whereas another 
patient, with seemingly similar tumor, survives. Thus, the identification of novel and 
evaluation of present breast cancer biomarkers are vital steps in the progression of improving 
the survival rate of breast cancer patients. 
Estrogen receptor alpha (ERα) is expressed in around 70% of the tumors. ERα is a good 
prognostic and predictive biomarker since it can effectively be targeted by endocrine 
treatment. The gene Dyslexia 1 candidate 1 (DYX1C1) has been shown to be overexpressed 
in cancer and also to regulate and be regulated by estrogen and its receptors. We evaluated 
the expression of DYX1C1 mRNA and protein in three independent breast cancer cohorts 
and its association to known breast cancer biomarkers and survival (study 1). We observed 
that DYX1C1 expression was positively associated with ERα expression and also functioned 
as a prognostic marker for improved survival.  
Biomarker expression in breast cancer is usually examined using immunohistochemistry 
(IHC) on whole tumor sections. During the diagnostic process, cells from fine-needle 
aspirations are usually examined, sometimes also by immunocytochemistry (ICC). ICC is 
also useful in a metastatic setting, and it is therefore important that the results are concurrent 
with IHC evaluation. We retrospectively examined paired IHC and ICC evaluation of ERα, 
progesterone receptor (PR) and Ki67 (study 2). We found that there were significant 
differences in the grading using IHC compared to ICC. Thus, to ensure the proper 
pathological diagnosis of metastatic lesions, comparisons and validation of these methods to 
detect biomarker should be performed.  
Estrogen receptor beta 1 (ERβ1) is expressed in both normal mammary tissue and malignant 
breast tumors. In vitro data point towards a protective role of ERβ1 with lower proliferation 
and less invasiveness when overexpressed. However, in vivo data are so far inconclusive, 
where some previous studies have reported better a prognosis, while others have reported no 
association or even a worse prognosis. We examined ERα, ERβ1 and splice variant ERβcx in 
breast cancer patients with clinically negative lymph node status (study 3). We found that 
ERβ1 was an independent marker of good prognosis. Interestingly it was expressed in 
patients of all grades and age groups, whereas ERα was commonly expressed in low-grade 
tumors of older patients. ERβcx did not show any prognostic association, nonetheless, high 
expression was coupled to risk of synchronous lymph node metastasis.  
  
Breast cancer stem cells have been shown to be highly tumorigenic, thus functioning as a 
biomarker of poor prognosis. The origin of these cells is not completely understood. Either 
they derive from normal stem cells or they are transformed from differentiated cells of the 
bulk tumor. Through exome sequencing we found that isolated breast cancer stem cells and 
mixed cells from the bulk of the tumor did not differ genetically (study 4). We showed that 
mutations were present in both stem cells and non-stem cells of the bulk tumor and at the 
same allele frequency. Our data supports a transformation of stem cells from differentiated 
cells. 
In conclusion, the evaluation of new and existing cancer biomarker has the potential to 
generate novel hypothesis on tumor biology and reveal new targets for treatment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SVENSK SAMMANFATTNING 
Bröstcancer är den vanligaste cancerformen bland kvinnor, och ungefär en av nio kvinnor i 
Sverige drabbas någon gång under sin livstid. Antalet som insjuknar i bröstcancer ökar 
stadigt, men trots det så dör inte fler av sjukdomen, utan dödsfallen minskar snarare något. 
Anledningen till detta tros vara att fler tumörer upptäcks tidigt, t.ex. genom 
mammografiscreeningen, samt att behandlingsalternativen blivit bättre Ett sätt att förbättra 
behandlingsmöjligheterna är genom identifiering och evaluering av så kallade biomarkörer 
för bröstcancer. Biomarkörer kan bland annat vara proteiner, gener eller celltyper som 
förutsäga hur en kvinna kommer svara på en viss typ av behandling eller vilken prognos hon 
har att överleva sjukdomen.  
Östrogenreceptor alfa (ERα) är en av de viktigaste biomarkörerna i bröstcancer och återfinns 
i ca 70 % av tumörerna. Den är både en markör för god överlevnad och för om cancern 
kommer att svara på anti-hormonell behandling. Genen Dyslexia 1 Candidate 1 (DYX1C1) 
kopplades först ihop med risken för att drabbas av dyslexi. Senare fann man även att genen 
uttrycktes i vissa cancertyper, såsom bröstcancer. I studie 1 undersökte vi därför om 
DYX1C1 mRNA och protein var vanligare i olika typer av bröstcancer, samt om närvaron av 
DYX1C1 kunde förutspå chansen för patienten att överleva. Vi fann att DYX1C1 var 
vanligare i tumörer som även uttryckte ERα, samt att kvinnor som hade DYX1C1 proteinet i 
sina tumörer hade bättre chans att överleva än de som inte hade det. 
Som ett steg i diagnostiken av bröstcancer gör man en finnålspunktion av tumören. Detta görs 
för att undersöka risken för att tumören är elakartad. Ibland så undersöker man även bland 
annat nivåerna av ERα, progesteronreceptorn (PR) och proteinet Ki67 ifrån punktionen, 
genom så kallad immunocytokemi (ICC). En liknande undersökning görs även på den 
utopererade tumören, men kallas då immunohistokemi (IHC). Det är IHC undersökningen 
som till stor del ger underlag för den fortsatta behandlingen efter operationen. I vissa fall då 
en tumör senare spridit sig till andra organ måste dessa analyser göras med ICC då man oftast 
inte opererar ut dottertumörerna. Det är därför viktigt att analyserna med IHC och ICC har 
stor överenstämmelse. I studie 2 undersöktes detta genom att jämföra analyssvaren för ICC 
och IHC hos kvinnor som opererats för bröstcancer. Vi fann signifikanta skillnader mellan 
ICC- och IHC-analyserna för ERα, PR och Ki67. Detta talar för att ICC och IHC analyserna 
bör valideras mot varandra vid varje laboratorium för att försäkra att dottertumörerna inte får 
fel ERα, PR och Ki67 klassificering. 
Länge hade man endast funnit en östrogenreceptor, den tidigare beskrivna ERα. År 1996 fann 
man ytterligare en östrogenreceptor vilken då namngavs till östrogenreceptor beta 1 (ERβ1). 
Denna finns uttryckt i både normal bröstvävnad samt i bröstcancer. Försök på 
bröstcancercellinjer har visat att ERβ1 troligen har en skyddande effekt genom att minska 
celldelningen och spridningsförmågan hos cellerna. Resultaten från studier på patientmaterial 
har dock varit blandade, där vissa har visat att närvaro av ERβ ger ökad överlevnad samtidigt 
som andra inte har funnit den kopplingen. I studie 3 undersökte vi hur ERα, ERβ1 och en 
  
variant av denna, ERβcx, var kopplade till andra biomarkörer och till patientöverlevnad. Vi 
fann att uttryck av ERβ1 i tumörerna var kopplat till bättre överlevnad och att ERβ1 fanns 
hos kvinnor i alla åldrar och oberoende av utmognadsgrad. Även ERα var kopplad till bättre 
överlevnad, medan ERβcx däremot, förutspådde risken för att drabbas av en 
lymfkörtelmetastas.  
Bröstcancerstamceller har potential av att vara väldigt elakartade, där endast ett fåtal av dessa 
krävs för att bilda en tumör. Detta innebär att de kan anses vara en biomarkör för dålig 
prognos. Det är ej helt känt hur bröstcancerstamceller uppstår, men det finns två huvudsakliga 
hypoteser; antigen bildas de från friska stamceller, eller så tillbakabildas de från utmognade 
cancerceller. För att undersöka ursprunget av bröstcancerstamceller i studie 4 så jämförde vi 
mutationerna i dessa celler mot mutationerna i resten av tumören genom sekvensering av 
DNA. Vi fann att samma mutationer fanns i både bröstcancerstamcellerna och i resten av 
tumören, samt att frekvensen av mutationerna var lika. Detta stödjer hypotesen att stamceller 
uppstår från utmognade celler.   
Sammanfattningsvis så är identifiering och utvärderandet av biomarkörer ett viktigt steg i 
utvecklingen av nya hypoteser och framtida specifika mål för behandling.  
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1 INTRODUCTION 
1.1 THE MAMMARY GLAND 
1.1.1 Development and physiology 
The mammary gland is a unique organ only present in mammals and sets us apart from other 
animals. It functions as a source of nutrition and energy for the offspring through production 
of breast milk. The breast tissue contains epithelial-, mesenchymal-, immune- and endothelial 
cells (1).  
The development of the mammary gland starts during the embryogenesis and continues 
during adolescence, pregnancy and after menopause. The epithelial cells of the mammary 
gland have been hypothesized to have originated from apocrine sweat glands for more the 
300 million years ago (2).  
Much of the data on the developing breast have been obtained through mouse models, 
however, most stages and signaling pathways overlap between humans and mice (2). During 
the embryogenesis, cells from the ectoderm and mesoderm develop into the epithelial and 
stromal components of the mammary gland. At the moment, not all steps of the early 
embryonic development of human mammary gland are elucidated (2). There is little 
difference in the intrauterine mammary development between male and female fetuses (3). In 
mice, most of the signaling is done in para- or autocrine fashion. Key signaling molecules 
present are from the Wnt-signaling pathways and the fibroblast growth factor (FGF) 
pathways (2).  
Figure 1. Schematic representation of the ductal and lobular development from embryo until mature 
lactating breast. Branching increases during the development. Modified from Oakes et al. 2014 (4). 
Reprinted with permission under the Creative Commons Attribution License. 
The cells in this early stage of breast development will form a breast line and then migrate 
into the mesenchymal cells underneath and form what is known in mice as a placode (figure 
1) (2). The placode will then form a breast bud, where in humans multiple sprouts are created 
 2 
that will later unite at the nipple. The rudimental ductal units later elongate like the branches 
on a tree. After the branching of the ductal cells, a lumen will be formed. The mechanism is 
not clearly understood, but is believed to involve both apoptosis and autophagy (2). The 
epidermal layers of the skin will form the nipple through thickening and suppression of the 
formation hair follicles. The parathyroid hormone related protein and its receptor are thought 
to play a crucial role in the later stages of embryonic mammary gland development in mice 
(2). At birth the rudimentary mammary gland structure is in place for later maturation and 
development during puberty. 
At puberty the hormonal changes present in the female body lead to development of both the 
stroma and the epithelium of the mammary gland. Proliferation of fibroblasts and adipocytes 
are central during this stage of the development (3). Elongation and further branching of the 
end bud structures, formed in the fetal development, into terminal ductal lobular units 
(TDLU) also take place. TDLUs are blunt ended acini are considered the functional unit of 
the mammary gland (3).  
Several hormones are thought to play a vital role in the pubertal mammary gland 
development, among them human growth hormone (GH) and estrogen (figure 2) (2). GH 
stimulates the paracrine signaling of insulin like growth factor 1 (IGF1) from the stroma of 
the mammary gland. Knocking out either GH or IGF1 in mice, reduces the ductal formation 
of the mammary gland (5,6). Local IGF1 is thought to play a more important role than IGF1 
produced in the liver (7). Interestingly high levels of serum IGF1 have been linked to 
increased risk of breast cancer (8).  
Estrogen signaling and estrogen receptors (ER) are important in pubertal development. Their 
structure and signaling will be described in chapter 1.5 in more detail. Briefly, estrogen is a 
fat-soluble hormone, produced in the ovaries and the adipocytes (9). It exerts its effect by 
binding to the intracellular ER present in most tissues. There are two main ER subtypes; ERα 
and ERβ (10). Interestingly, during the mammary development ERα is not expressed in 
proliferating cells of the mammary tissue. The effect seems instead to be mediated mainly 
through paracrine signaling. Only a few cells with activated estrogen signaling are enough to 
drive the proliferation of the surrounding cells (11). This has also been shown in studies of 
ERα knockout mice, where the mammary development can be rescued by transplanting a few 
cells expressing ERα (12). The growth factors responsible for the paracrine signaling from 
the ERα expressing cells in the mammary gland are yet to be determined. However, several 
members of the epidermal growth factor (EGF) family such as Amphiregulin (AREG) have 
been suggested (2). AREG is believed to promote much of the proliferation seen by estrogen 
stimulation (13). It is strongly induced in mammary tissue during puberty, and knocking out 
Areg in mice leads to a phenotype similar to knocking out ERα. The AREG receptor is 
mainly located in the stromal cells and not in the epithelial cells of the mammary gland 
(14,15). The AREG signaling illustrates the complex and important cross talk between the 
stroma and epithelial cells in the mammary gland development in response to estrogens. 
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Figure 2. Schematic representation of the events, hormones and signaling molecules involved in the 
pubertal mammary development. Growth hormone (GH) released from the pituitary gland, stimulates 
the release of insulin like growth factor 1 (IGF1). Estrogen is released from the ovaries and binds to 
estrogen receptors (ESR). AREG and FGFs are important factors. For detailed explanation see the 
text. Modified from Macias and Hinck, 2012 (2). Reprinted with permission from John Wiley and 
Sons.  
Fibroblast growth factors (FGF) are other candidates for the paracrine cross talk and are 
believed to mainly signal through one of its receptors, FGFR2. It is located on the epithelial 
cells and induce proliferation and elongation of the glandular ducts (16,17). On the other 
hand, transforming growth factor β1 (TGFβ1) has been shown to be the main negative 
regulator of branching and elongation of the ducts. Presence of TFGFβ1 leads to an increase 
of the space between the ducts (18-20). The inter-ductal space is later used for alveolar 
outgrowth during pregnancy, in the preparation of the breast for lactation. To summarize, a 
balance between promoting and inhibiting factors are important during puberty to develop a 
mature mammary gland with developed and dispersed ducts (figure 3 displays the steps in 
mice mammary gland). 
The adult female mammary gland goes through several changes during pregnancy. A 
combination of a large proliferative burst together with novel alveolar formation, known as 
alveologenesis, takes place before the birth of the child. Shortly after partum this is followed 
by milk production and start of lactation. Later, after weaning of the offspring, an involution 
of the mammary gland takes place. This leads to a restoration of the gland to most of its pre-
pregnancy status (2). Again several hormones play a crucial part of the evolvement of the 
mammary gland of the pregnant female. The most important hormones are estrogen, 
progesterone, and the pituitary hormone prolactin (2). Due to ethical reasons, studies of 
healthy pregnant women are limited. Thus, data presented below have mostly been obtained 
from mouse models. Progesterone is similarly to estrogen a fat-soluble hormone with an 
intracellular receptor that function as a transcription factor (21). While progesterone does not 
seem to be obligate in the pubertal mammary development, it is vital for the branching and 
alveolar formation during pregnancy (22). Mice lacking progesterone receptor (PR) are 
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unable undergo alveologenesis. Overexpression of PR instead leads to increase in alveolar 
formation (23,24). PR is mostly expressed in the epithelial cells close to the lumen of the 
ducts. Although, the cells expressing PR do not seem to proliferate themselves, progesterone 
seems to promote proliferation in the mammary gland through paracrine signaling, similar to 
estrogen (25). The number of PR expressing epithelial cells decrease when mice become 
pregnant, from approximately 55% to 5% (23,26). 
Progesterone and prolactin seem to have similar functionality and are closely related in the 
pregnant mammary gland (27). For example, when the MCF7 breast cancer cell line is treated 
with progesterone, the levels of prolactin receptor increase. The same happens for PR when 
treated with prolactin (28). The receptor activator NFκB ligand (RANKL) has been suggested 
to be responsible for some of the crosstalk between progesterone and prolactin (27). 
Furthermore, prolactin is important in the alveologenesis during pregnancy. Prolactin is also 
responsible for the continuation of lactation after partum and breast-feeding increases the 
release of the hormone from the pituitary gland (27).         
The involution of the mammary gland happens upon weaning of the child and occurs in two 
steps (figure 3). Initially, there is massive apoptosis of the alveolar structures, mediated by 
local factors within the gland (3). Many of the mediating factors involved are known, 
however; the initiating trigger of apoptosis is unknown. The second irreversible step results in 
a dramatic remodeling of the gland. The end result is a structure more similar to that of the 
gland before pregnancy (2). However, the breast will not return completely to its pre-
pregnancy state, since much of the branching of the ducts will remain. During menopause 
involution of the mammary gland also takes place. Leading to epithelial structures and inter-
lobular connective tissue being replaced by adipocytes (1). 
 
Figure 3. The development of the mammary gland in mice. From birth, adolescence, puberty, fertility, 
pregnancy, lactation and involution. Although the time points are different in humans, the overall 
development is similar as is the hormones responsible. Modified from Macias and Hinck, 2012 (2). 
Reprinted with permission from John Wiley and Sons.  
1.1.2 Histology and anatomy 
The female breast consists of many cell types, making up the epithelial and stromal 
compartment of the gland. The glandular part of the breast consists of epithelial cells that are 
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organized into ducts and lobes (figure 4). This is interspaced with connective tissue, made up 
of extracellular matrix and adipocytes (1,29). The fibrous connective tissue is organized into 
suspensory ligaments known as Coopers ligament. At the nipple, approximately 25 main 
ducts have their ending (1). The lobes are made up of smaller lobules that contain between 
10-100 alveoli; this grouping is denoted as TDLU as described earlier. The alveoli are the 
location of the milk producing cells.  
 
Figure 4. Schematic drawing on the anatomical structure of the mammary gland. Modified from Ali 
and Coombes, 2002 (30). Reprinted with permission from Nature Publishing Group. 
The ducts and lobes of the human mammary gland epithelium are two cell layers deep. The 
inner cell layer, closest to the lumen, consists of cuboid epithelial cells known as luminal 
cells. These later become the milk producing cells during lactation (1). The outer layer is 
made up of myoepithelial cells. They surround the luminal cells and are believed to function 
similar to smooth muscle cells to propel the milk forward. Beneath the myoepithelial cells is 
the basal membrane, and also interspersed mammary stem cells that can mature into the two 
differentiated cell types (1). The stroma surrounds the epithelial compartment and is made up 
extracellular matrix protein such as collagens with scattered fibroblast, adipocytes and cells 
from the immune system.      
The blood supply to the mammary gland comes from branches of the internal mammary 
artery and the lateral thoracic artery (1). During pregnancy and lactation, the blood flow 
increases to meet the subsequent increase in demand of nutrients and oxygen of the mammary 
tissue. The increased blood flow also transports immune cells into the gland and antibodies 
into the milk. The lymphatic system has received much attention due to its role in the spread 
of disseminated cells from breast cancer tumors (1). Most of the lymphatic fluid is drained to 
the axillary lymph node, both from the lateral and medial part of the breast. Whereas the deep 
parts are drained into internal lymph nodes of the breasts however, there is large individual 
variation (1).      
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1.2 BREAST CANCER 
Breast cancer is the malignancy with highest incidence and deaths in women worldwide with 
1.38 million new cases and 458.400 associated deaths in 2008 (31). Breast cancer affects 
women in both developed and developing countries (figure 5). While, the incidence is higher 
in developed countries, the risk of dying of the disease is higher in developing countries (31). 
The difference in incidence between countries is partially explained by variations in the use 
of hormone replacement therapy and reproductive patterns, such as age at first child, number 
of children, age at menarche and nutritional factors (32). Furthermore, the variation in 
detection rate due to availability of mammography screening and medical care, also explain 
some of the differences (33). Other factors such as high alcohol intake, obesity and inactivity 
have also been linked to risk of developing breast cancer (34).  
 
Figure 5. Incidence and mortality from breast cancer in 2008 of different regions of the world. 
Incidence (green bars) is highest in Europe, North America and Australia/New Zeeland. Mortality (red 
bars) is more equally distributed, highest rates are seen in Africa. Displayed as age standardized rates 
per 100.000. From Jemal et al. 2011 (31). Reprinted with permission from John Wiley and Sons.  
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1.2.1 Cancer development 
The development of cancer is a multistep process. A normal cell can through several changes 
in its genome, both genetic and epigenetic, obtain abilities that are vital for a malignant cell. 
In a review from 2000, Hanahan and Weinberg introduced a simplistic cancer model with six 
hallmarks, all needed to form a malignant tumor from a normal cell (35). Later in 2011, two 
enabling and two emerging hallmarks were added to the six. The authors have been able to 
condense the vast scientific field of cancer into ten abilities, which are universal to all solid 
cancer tumors (36). The original six hallmarks were: “evading growth suppressors”, 
“resisting cell death”, “sustained proliferative signaling”, “inducing angiogenesis”, 
“replicative immortality”, “tissue invasiveness and metastatic properties”. The two new 
emerging hallmarks from 2011 were: “avoiding immune destruction” and “deregulating 
cellular energetics”, and the two enabling: “genomic instability” and “tumor promoting 
inflammation” (figure 6).  
 
Figure 6. The ten hallmarks of cancer. The original six were presented by Hanahan and Weinberg in 
2000. In 2011, two enabling and two emerging were added. Modified from Hanahan 2011 (36). 
Reprinted with permission under the Elsevier user license.  
Different cancer types, but also different tumors from the same cancer type, acquire these 
hallmarks in different ways. The sustained proliferative signaling can be obtained by inducing 
growth factor receptor expression. For example in breast cancer, the ERBB2 gene that 
encodes the HER2 receptor tyrosine kinase, is often amplified leading to overexpression and 
increased proliferation (37). Furthermore, signaling pathways can be activated or lose their 
normal inhibition. In breast cancer, the PIK3CA gene that transcribes the PI3K protein kinase 
is often constitutionally activated by mutations resulting in increased proliferation (38). 
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Evading growth suppressors is acquired mainly by loss-of-function mutation, deletions or 
downregulation of protein expression. The tumor suppressor gene TP53 is commonly 
mutated which leads to inactivation of P53 and avoidance of apoptosis. This is especially 
common especially in more aggressive breast cancers (39). There several more ways by 
which cancer cells can evade apoptosis.  
To obtain replicative immortality, the cancer cell needs to avoid the normal state of 
senescence, where the cell continues to exists without proliferating. Senescence is believed to 
occur when the telomeres of the chromosomes become too short (40). Overactivity of the 
telomerase enzyme, which lengthens telomeres, has been shown in several cancers including 
breast cancer. In normal epithelial cells, expression of the telomerase gene TERT is not 
detectable. On the other hand, in invasive breast cancer it is expressed in more than 90% of 
the tumors (40).  
The rapid proliferation rate and high metabolic activity of cancer cells result in a high 
demand of nutrients and oxygen to the growing tumor. It has been suggested that tumors are 
unable to become larger than a few millimeters before their growth is inhibited by lack of 
these factors (41). Thus, the tumor has to be able to induce the formation of novel blood 
vessels, known as angiogenesis, from the surrounding normal tissue. This is considered to be 
an early event on the progression from pre-malignant to malignant tumors.  
One of the most important differences between benign and malignant tumors is the potential 
of local tissue invasion and distant metastasis (42). The downregulation of cell-to-cell 
adhesion molecules is a common event in malignant tumor development (29). The ability of 
cancer cells to undergo epithelial-to-mesenchymal transition (EMT) is mediated through the 
re-activation of embryonic transcription factors and loss of adhesion. Resulting in a 
transformed epithelial cell that is able to survive despite the loss of cell-to-cell contact, invade 
nearby tissues, and later disseminate and migrate through blood or lymphatic vessels (43). 
Genetic instability is one of the two novel enabling hallmarks (36). Having a genome where 
structural changes and mutations occur at a higher rate than in normal cells most often leads 
to loss of fitness for the individual cancer cell. However, this also leads to faster acquisition 
of novel abilities for some of the tumor cells, replacing the less fit cells. P53 plays an 
important role by inducing apoptosis if damages to the genome are found. Furthermore, 
BRCA1 and BRCA2 function as DNA repair genes to protect the stability of the genome. 
Having a germline mutation in either BRCA1 or BRCA2 results in a high risk of developing 
breast cancer (44).  
The second enabling hallmark “tumor-promoting inflammation” and one of the emerging 
hallmarks “immune destruction evasion”, both involves the immune system in tumor 
development. When examining breast cancer sections histologically, many contain 
infiltrating immune cells. In immune deficient mice, the risk of developing tumors is 
increased. Humans undergoing immune suppressing treatment after organ transplantation 
have a higher chance of developing cancer derived from the donor organ (45). The immune 
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system is able to detect and eliminate many of the early stages of cancer. It has been 
estimated that as much as 80% of non-infectious cancers are eliminated before they can be 
detected (36). However, a tumor that has grown to a discoverable size has acquired the ability 
to avoid the immune system. In these tumors the presence of immune cells can instead 
promote the growth of the tumor. The release of growth factors from the immune system is 
believed to induce angiogenesis, proliferation and to modify the extracellular matrix in the 
tumor (36).  
The second emerging hallmark is the ability to reprogram the energy metabolism of cancer 
cells. Many cancer cells are able to change their cellular metabolism from oxidative 
phosphorylation to rely heavily on glycolysis even though there still sufficient oxygen present 
(46). The reason for this switch is not clearly understood. It may intuitively seem unfavorable 
to rely on glycolysis since the energy produced per glucose molecule is much lower than for 
oxidative phosphorylation. It has been hypothesized that the production of other metabolic 
by-products needed for the fast replication of the genome may be the reason for the change in 
metabolic systems (46). A consequence of the decrease in oxidative phosphorylation would 
be lower oxygen consumption, but increase in glucose demand (36). 
1.2.2 Breast cancer development       
Breast cancer is believed to develop from the epithelial cells of the TDLUs in the mammary 
gland. The exact molecular steps of the progression from normal epithelium to invasive 
breast cancer are not completely understood. A breast tumor is considered malignant when it 
has invaded the surrounding tissue by passing through the underlying myoepithelial cells and 
basement membrane (47). To be able to transform from benign cancer in situ to invasive 
cancer, the myoepithelial cells need to lose their ability to contain the dysplastic cells. The 
mechanism of this is not clearly understood (48).  
Several pre-malignant stages have been found in the mammary gland. These are ranging from 
hyperplasia, atypical hyperplasia, cancer in situ, to invasive cancer (47). The classical breast 
cancer development model is based on a stepwise progression from non- to pre- to malignant 
states, similar to the model proposed in colorectal cancer (48). This model was based on 
morphological studies of the changes found during histological examination. However, 
subsequent experimental studies have indicated that the process of breast cancer development 
is more complex (48). Many of the precursor stages may not be obligate, and not present in 
the development of all breast cancers. Also, not all pre-malignant lesions develop into cancer. 
Though, the presence of these indicates a higher risk of later invasive breast cancer 
development (47). Instead, it seems that tumors of different histological grades and subtypes 
have developed through different progression pathways (48). It has been shown in several 
studies that common losses and gains of chromosomal regions present in pre-malignant 
lesions are not present in all malignant tumors (48). Consequently, breast cancer today is not 
considered as one single disease but several malignancies originating from one organ (48).  
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Tumors have historically been classified according to histological type, where the two most 
common are ductal or lobular cancers, however many more exist. This division has shown 
some prognostic value (49). When examining the karyotype of breast cancer of different 
histological types, a overlap have been identified, thus indicating a non-perfect division (49). 
Counting the number of genetic aberrations in invasive lobular and ductal cancer, fewer are 
found in lobular cancer, which may reflect the average lower grade of lobular cancer (49).  
One of the non-obligate benign precursors of ductal cancer is called hyperplasia of usual type 
(HUT) and show non-atypical intraductal growth. Only a few percent of the HUTs are 
believed to progress towards atypical ductal hyperplasia (ADH) and later ductal cancer in situ 
(DCIS) or to invasive cancer (48). HUT is instead mainly seen as a marker of risk for a 
female of developing invasive breast cancer. The benign histological precursor ADH, which 
has been seen as both a risk indicator and a non-obligate precursor, often shares many of the 
characteristics of low-grade DCIS. For example ERα and PR expression and lack of HER2 
overexpression is common. Also the chromosomal aberrations are often the same between 
ADH and DCIS. Therefore there is no clear division between ADH and low-grade DCIS, 
instead a gradual shift takes place between the two (48). High grade DCIS is a non-obligate 
precursor of invasive ductal cancer and its presence is a strong predictor of later developing 
invasive breast cancer. High grade DCIS cells show high nuclear pleomorphism and necrosis 
is often present. However, since the cancer cells have not invaded through the underlying 
myoepithelial cells this state is considered benign. Most of the genetic and gene expression 
changes seen in invasive cancer can be found already in DCIS (48). 
Lobular cancer has similar benign precursor stages as ductal cancer with atypical lobular 
hyperplasia (ALH) and lobular cancer in situ (LCIS). Both are risk indicators of developing 
invasive breast cancers as well as non-obligate precursor stages. The risk of developing 
invasive breast cancer is higher with LCIS than with ALH although the risk is low for both 
precursors. Analogous to ADH and DCIS, the division between ALH and low-grade LCIS 
has been considered to overlap by some (48). ALH have similar but more differentiated 
morphology compared to LCIS and the expression pattern of ERα, PR and HER2 show large 
similarities. High grade LCIS is often called pleomorphic lobular cancer in situ (PLCIS) and 
is considered a non-obligate precursor stage of invasive lobular cancer. PLCIS is 
characterized by pleomorphic, atypical nuclei, moderate proliferation and sometimes 
comedo-like necrosis. Differently from ALH and low-grade LCIS, the expression of ER and 
PR is usually low and HER2 is commonly overexpressed (48).      
1.3 STEM CELLS 
1.3.1 Stem cells in the healthy breast 
Because of the cycling nature of the adult mammary gland it was long believed that there are 
cells within the gland with stem cell capabilities. These should be able to drive the 
proliferation needed during different stages in life during puberty, pregnancy, and menopause 
(50). In mice, it was early shown that by transplanting pieces of mammary tissue, to a mouse 
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without mammary gland, a whole gland could be regenerated (51). Later, a putative stem cell 
that was able to self-renew and reconstitute novel breast structures in mice was identified 
(50). The mammary stem cells (MSC) are believed to be present at only small numbers and 
give rise to both luminal and myoepithelial cells of the epithelium (4,52). Many MSC surface 
markers have been identified, such as Sca-1, CD24, CD49f, CD44, and ALDH1 (4,52). 
These can be used to both isolate and identify MSC.  
Another way of identifying and isolating MSC is to make use of their capability to form free-
floating cell aggregations, called mammospheres. When grown in serum free medium in non-
adherent flasks the MSC aggregates together (53). The method of isolating and growing MCS 
was adopted from experiments from neurological stem cells (54). Epithelial cells that lose 
contact with either the extracellular matrix or other cells undergo apoptosis (55). This 
property is known as anoikis and exist to retain the organization of the epithelium and prevent 
dissemination of cells (56). Stem cells have the ability to prevent anoikis and survive in non-
adherent conditions (57). Mammospheres are therefore highly enriched of cells with stem cell 
capabilities. It has been shown that a single cell from a mammosphere is able to form 
multilineage colonies when let to differentiate (53). MSCs are interesting for the development 
of cancer because of their longevity and ability to replicate many times, although the 
proliferation rate is low (52).  
1.3.2 Stem cells in breast cancer 
The existence and importance of stem cells in cancers were first described in leukemia. In 
leukemia only a subset of cells is able to reconstitute the disease after xenotransplantation 
(58,59). This discovery challenged the prevailing theory of the clonal evolution of cancer 
development, which states that any cell has equal probability of driving tumor development 
and proliferation (60). In breast cancer, the first potential cancer stem cells were described by 
Al-Hajj et al. in 2003 (61). They were identified as CD44+/CD24-/low expressing cells and 
were over 50 times more tumorigenic than a mixed cell population to form new tumors (61). 
Therefore they can be considered as biomarkers of poor prognosis. Later, several other 
markers for identifying and isolating breast cancer stem cells (BSC) have been proposed, 
such as ALDH1, PKH26, DLL1 and DNER (4,62,63).  
Mammosphere formation can also be used to isolate BSC (63). However, none of the 
suggested biomarkers seems to universally detect all stem cells, which remains one of the 
main controversies regarding the presence of BSC. The non-complete overlap results in that 
all CD44+/CD24-/low cells do not express ALDH1 and there are a few cells within the 
mammospheres that are not CD44+/CD24- or ALDH1high. Critics against the presence of BSC 
have also argued that the CD44+/CD24-/low cells may perhaps only be a subset of cells that are 
more suitable for xenografting, instead of being true stem cells (64).  
There are differences in the prevalence of stem cells among the different intrinsic subtypes 
(described in chapter 1.4.8). For example the CD44+/CD24-/low cells are more common in 
Basal subtype, whereas ALDH1high are more common in HER2 enriched tumors (65). Breast 
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cancer stem cells are also thought to be more common in the Claudin-low tumors than for 
example in Luminal A and Luminal B cancers (66). CD44 is the most commonly expressed 
stem cell marker in primary breast cancer with as much as 50% of the cells of the being 
positive. ALDH1 and CD24 are less common and expressed in fewer cells (65).  
 
Figure 7. Schematic representation of the two main breast cancer stem cell models. According to the 
hierarchal model, cancer stem cells (red dots) they are able to renew and divide into more 
differentiated cancer cells (green squares). In the plasticity model differentiated cancer cells can revert 
back into cancer stem cells. Inspired by Gupta et al. 2011 (67). 
1.3.3 Origin of stem cell in breast cancer 
Several theories regarding the origin of BSC have been proposed. Two different main 
hypotheses are considered likely (figure 7) (68,69). The first, “Hierarchical division” 
suggests that cancer stem cells originate from the mammary stem cells of the normal gland 
(70). This means that several genetic modifications have taken place within the normal stem 
cell, resulting in it becoming malignant and causing the disease. The hierarchal model was 
the first hypothesis to receive support since it resembles how many normal stem cells are 
thought to behave. In this model one stem cell give rise, irreversibly, to the differentiated 
cells of the tumor. However, the model, has later received criticism since it cannot explain 
some of the characteristics seen in solid tumors (68,70). For example, the heterogeneity 
observed in tumors is difficult to explain with only one stem to cell give rise to the whole 
tumor. The presence of heterogeneity instead point towards a multiclonal evolution of the 
tumor with several subpopulations (70). Although stem cells have been found in normal 
mammary tissue, cancer stem cells do not have to originate from these. Their slow 
proliferation rate would make them less susceptible to transcriptional errors and subsequently 
mutations. On the other hand, their longevity makes it possible to accumulate mutations over 
time.  
The second hypothesis proposes a stochastic plasticity model, where differentiated cancer 
cells have the potential to de-differentiate back into a more stem cell like state. These cells 
then drive the development and renewal of the tumor (64,71). The de-differentiation 
mechanism has been suggested to occur through changes in gene expression and mediate 
epithelial-to-mesenchymal transition (EMT) where epithelial cells transform into cell with 
Bulk tumor cells
No tumor 
f rmation
Cancer stem cells
Tumor formation
Cancer stem cells
Tumor formation
Bulk tumor cells
No tumor 
formation
Hierarchal model Plasticity model 
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mesenchymal properties (72). EMT happens readily during the embryonic development and 
is also believed to be the mechanism to why some cancers metastasize (68). The hypothesis 
of breast cancer stem cell plasticity has the potential to unify clonal evolution theory with the 
stem cell theory, the two hypotheses of breast cancer origin (64). Recently, the Nobel Prize 
was awarded for showing that differentiated cells could be reprogrammed into pluripotent 
stem cells, so called iPS-cells. By inducing four different transcription factors cells could be 
de-differentiated into stem cells, this could plausibly also happen in vivo (73). Breast cancer 
cell lines can be stimulated to generate cells with stem cell like properties and express 
CD44+/CD24-/low cells under certain conditions (74). The function and origin of cancer stem 
cells may be different in different cancers and more work is needed to fully understand the 
presence and role of stem cells in breast cancer. However, evidence is accumulating that 
cancer stem cells are cells that have acquired a stem cell like phenotype instead of being a 
group of cells with a specific genotype (67).  
1.3.4 Cancer stem cells and therapy resistance 
Studies have shown that cancer stem cells are less susceptible to conventional chemotherapy 
and radiotherapy (75,76), and several mechanisms have been proposed. For instance, up-
regulation of detoxifying enzymes, efflux pumps, DNA-repair enzymes, and less response to 
apoptotic signals (77). This means that there is a need to develop novel drugs targeting this 
type of cancer cells (64). Several potential targets in breast cancer stem cells have been 
identified, among them Interleukin 8 receptor and DLL4 receptor, and intracellular enzymes 
part of the JAK/STAT pathway (62,69). Because of the possible ability of breast cancer cells 
switching between a differentiated and a stem cell like state, suggestions have also been made 
towards a combined therapy targeting the differentiated cells with conventional therapy and 
the stem cells with targeted therapy at the same time (78).      
1.4 PROGNOSTIC AND PREDICTIVE FACTORS IN BREAST CANCER 
1.4.1 Lymph node metastasis 
The strongest prognostic factor in breast cancer is lymph nodes metastasis (79). The 
disseminated cancer cells from the tumor are most often transported by the lymphatic system. 
These cells can then settle the local or axillary lymph nodes, and form a lymph node 
metastasis. The lymph nodes have been proposed to function as filters where the cancer cells 
can be eliminated by the immune system, thus preventing spread to the systemic circulation 
and distant metastasis (47). A metastasis to the lymph nodes merits further surgical removal 
of all axillary lymph nodes. It often means that up to 20-30 lymph nodes will be removed. 
This procedure has shown to decrease the risk of local recurrence; however, if it protects 
against systemic metastasis is still not clear (80-82). Since lymph node metastasis is coupled 
to worse prognosis, these patients often require systemic chemotherapy and more extensive 
radiotherapy. Removal of the axillary lymph nodes sometimes leads to lymphedema of the 
arm, which is associated with reduced quality of life. Other side effects include neurological 
pain and limited shoulder and arm movement (83). To decrease the number of non-necessary 
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axillary dissections, the sentinel lymph node (SLN) biopsy surgical technique was developed 
(84,85). In clinically lymph node negative women, a blue dye and radioactive labeled fluid is 
injected in the breast prior to surgery. This helps the surgeon locate the first lymph node 
responsible for draining lymphatic fluid from the tumor, the so-called SLN. It has been 
shown that if the SLN is free from metastasis, this is associated with a low risk of spread to 
other lymph nodes, in some studies less than 10% (86,87). Therefore the benefit of removing 
all axillary lymph nodes in SLN negative patients does not outweigh the risk of developing 
adverse effects of the surgery. Furthermore, studies have been unable to show increased 
survival in node negative patients with extended axillary dissection (88).   
1.4.2 Estrogen receptor alpha 
ERα is one of the most important biomarkers, approximately 70% of all primary breast 
cancers are ERα positive. ERα is considered a good prognostic and predictive marker for 
endocrine treatment (89). In a study where no chemotherapy was given, the 5-year overall 
survival was 92% in ERα positive tumors compared to 82% in ERα negative tumors (90). 
However, evidence also point towards that ERα loses its prognostic potential with longer 
follow-up; after 5 years much of the difference is gone (91). Hence, it has been suggested that 
ERα expression denotes slower but similar potential of distant metastasis and death (79). The 
importance of ERα to predict response to anti-estrogen treatment is used clinically on a daily 
basis. There are three different classes of anti-estrogen treatments available with different 
modes of action; selective estrogen receptor modulators (SERMs) e.g. tamoxifen; aromatase 
inhibitors (AI); and the estrogen antagonist fulvestrant. Traditionally, a cut-off of 10% of 
positive cells has been used to separate positive from negative tumors. However, in 2010 the 
American Society of Clinical Oncology (ASCO) and College of American Pathologists 
(CAP) changed their guidelines and a new cut-off of 1% was implemented (92). The Swedish 
cut-off guideline is still at 10% positive cells. It has been shown that even patients with only 
little expression of ERα seem to benefit from endocrine treatment (93). In women with ERα 
positive tumors targeting ERα is effective, reducing the risk of recurrence by half for the first 
5-years and by a third the following 5-years when given tamoxifen (94). It has also been 
shown that women with ERα negative tumors do not benefit from treatment with tamoxifen 
at all (94). 
1.4.3 Progesterone receptor 
Progesterone receptor (PR) is strongly associated with ERα expression and is measured as a 
marker of intact ERα signaling. It is therefore believed that PR expression better predict 
which patient who will respond to endocrine treatment (25,92,94). PR is a target gene of ERα 
activation. Treatment with estrogen leads to increased PR levels in breast cancer cell lines 
(95). Several estrogen receptor-binding sites, so called estrogen response elements (ERE), 
upstream of the PR gene, are believed to mediate the activation (96). The prognostic value of 
PR has been shown in several studies, even independent from ERα and other prognostic 
markers (97,98). There is today no cancer treatment that specifically targets PR.       
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1.4.4 Proliferation rate 
The proliferation rate of the breast cancer cells is routinely measured by 
immunohistochemical staining of the Ki67 protein. Although its function is unknown, Ki67 is 
expressed in proliferating cells throughout the cell cycle (99). The Ki67 index is particularly 
important in the clinical decision making when determining between giving chemotherapy or 
not in ERα positive tumors. Thus, the Ki67 index can be used to discriminate between tumors 
with high or low risk of recurrence. But it can also be used as a proxy to discriminate between 
different intrinsic subtypes, such as tumors from the low proliferating Luminal A subtype 
with good prognosis, against Luminal B tumors with high proliferation and poor survival 
(100). However, there have been reports of variability in the reporting of Ki67 both between 
and within labs (100). Consequently, no general cut-off have been established to distinguish 
between tumors of high and low proliferation (101).  There have also been discussions on 
how to analyze Ki67 most reliably in order to predict benefit of chemotherapy. Today most 
consider counting the percentage of Ki67 expressing cells within the areas of highest 
proliferation, the so-called hot spots, to be the most accurate (102).              
1.4.5 HER2 
HER2 is a biomarker that has evolved from a marker of poor prognostic into a predictive 
marker of treatment response (79,103). The protein is transcribed from the ERBB2 gene 
located on chromosome 17. HER2 is a transmembrane receptor, which functions as a tyrosine 
kinase, although the endogenous ligand has not been discovered (104). Overexpression of 
HER2 was long seen as a poor prognostic marker until the development of the first targeted 
therapies. Without targeted treatment the patients have increased mortality and relapse rate 
(105). This is especially evident in node-negative patients (106). Today, using treatments 
targeting the HER2 receptor, the survival of these patients has improved dramatically (107). 
Early data described HER2 to be overexpressed in as high as 30% of tumors (108). However, 
due to better testing, the percentage of reported positive tumors has decreased to 15-20%, 
hence fewer false positive tumors are reported (109). To benefit from the anti-HER2 
treatment the receptor needs to be overexpressed and also the gene amplified (104).  
1.4.6 Staging 
Staging of breast cancer patients reveals a great deal of information on the prognosis for the 
individual patient. In breast cancer, staging is performed according to the TNM classification 
system (110). This system is used in many cancers and divides the tumors into stage 0-4 
depending on tumor progression. The factors taken into consideration are the size of the 
primary tumor (T), spread to loco-regional lymph nodes (N), and distant metastasis (M) 
(table 1) (110). Stage 0 is non-invasive cancer e.g. DCIS and LCIS. Stage 1-3 breast cancer 
(without distant metastasis) is today considered curable, while stage 4 breast cancer (with 
distant metastasis), is considered incurable. This is indicated by a meta-analysis on the 
prognosis from 36 clinical trials with metastatic disease showing a mean median overall 
survival of 21.7 months (111).  
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In node negative women, the size of the tumor is the most valuable independent prognostic 
factor (79). In women with tumors smaller than 1 cm, the 5-year overall survival has been 
reported to be as high as 99%. However, patients with 3-5 cm tumors had an overall survival 
of 86% (112). Furthermore, the mean time to distant metastasis was shorter for larger tumors 
compared to smaller tumors (113). The introduction of the mammography screening program 
has increased the number of early-detected tumors. This has led to that the average size of the 
tumors is now less than 2 cm (114).     
Stage Tumor (T) Node status (N) Metastasis (M) 
Stage 0 Tis N0 M0 
Stage IA T1 N0 M0 
Stage IB T0-T1 N1mi M0 
Stage IIA T0 N1 M0 
 T1   N1 M0 
 T2 N0 M0 
Stage IIB T2 N1 M0 
 T3 N0 M0 
Stage IIIA T0   N2 M0 
 T1* N2 M0 
 T2   N2 M0 
 T3   N1 M0 
 T3 N2 M0 
Stage IIIB T4   N0 M0 
 T4   N1 M0 
 T4 N2 M0 
Stage IIIC Any T N3 M0 
Stage IV Any T Any N M1 
Table 1. Breast cancer staging. Tis = cancer in situ. T0 = no evidence of primary tumor. T1 = 0-2 
cm. T2 = 2-5 cm. T3 = >5 cm. T4 = any size and growth to skin or chest wall. N0 = no lymph node 
metastasis. N1mi = metastasis between 0.2-2.0 mm. N1 = 1-3 axillary metastasis or 1 internal 
mammary node metastasis larger than 2.0 mm. N2 = 4-9 axillary lymph node metastasis. N3 = more 
than 10 node metastasis or metastasis to infra- or supraclavicular lymph nodes. N status can also be 
classified clinically. M0 = no distant metastasis or smaller than 0.2 mm. M1 = distant metastasis 
larger than 0.2 mm. Source UICC 7th edition TNM classification manual (110).   
1.4.7 Histological grade 
The differentiation grade of the tumor is used as a prognostic factor. There are several 
methods to evaluate the differentiation of the tumor. One of the most used and well validated 
is the Nottingham histological grading system (also called Elston-Ellis) (115). This grading 
system was developed from the Bloom-Richardson system by introducing numerical cut-offs 
for two of the three criteria (116,117). The criteria examined in the Nottingham grading 
system are tubular formation, nuclear pleomorphism, and mitotic count. Each is given a score 
between 1-3 which are then combined into a total score (116). The tumors are then divided 
into three separate grades; grade 1, tumors with a total score of 3-5; grade 2, total score of 6-7 
and; grade 3, total score of 8-9 (116). As a group, grade 1 tumors have the best prognosis, and 
grade 3 have the worst (116,117). It has been shown that grade 2 tumors are a somewhat 
more common than grade 1 and grade 3 (117,118). However, the existence of grade 2 tumors 
has been debated. Some argue that tumors classified as grade 2 are in fact a mix of grade 1 
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and grade 3 tumors (119). The gene expression pattern of grade 2 tumors does not seem to be 
of a distinct type but instead match either grade 1 or grade 3 tumors (119). Also, analyses of 
chromosomal aberrations in different tumor grades have shown, contradictory to what was 
earlier believed, that progress from low- to high-grade tumors seldom happens. Common 
aberrations found within low-grade tumors are not found when examining high-grade tumors 
and vice versa (49). For example, loss of chromosome arm 16q and gain of 1q is common in 
low-grade tumors but is rare in high-grade tumors (48). This is especially evident in ERα 
positive tumors (48). High-grade tumors often have overexpression of HER2 but lack ERα 
and PR expression and have complex karyotypes with deletions and amplifications seen 
among many chromosomes (49).  
1.4.8 Intrinsic subtypes 
With the development of gene expression DNA microarrays, a novel way of classifying 
breast cancer was introduced in the early 2000s (120,121). By measuring the gene expression 
level of several thousands of genes in breast cancer tumors, a set of genes was identified that 
were differently expressed between tumors. Using this gene set, the tumors could be divided 
into distinct groups with similar gene expression pattern (121). The classification was called 
the intrinsic subtypes (molecular subtypes) and four principal subtypes were discovered 
(table 2). The main dividing factors in the clustering of the tumors were positive ERα 
expression status (120). Protein expression of keratin 8/18 was also common in this group. 
Since genes associated to the luminal cell type were overexpressed, the group was called the 
Luminal subtype (120). The Luminal tumors were later divided into two groups; Luminal A 
and Luminal B. The Luminal A subtype showed higher ERα expression and lower 
proliferation rate than Luminal B tumors (122). In the group of ERα negative tumors there 
was a group of tumors expressing genes common in myoepithelial cells, thus known as the 
Basal subtype (120). Another group of tumors within the ERα- negative group showed 
overexpression of HER2 and genes associated with HER2, thus called HER2-enriched (120). 
A final cluster of the ERα-negative tumors showed similarities to the expression of normal 
mammary specimens, and were then named Normal-like (120). The normal-like subtype has 
been questioned, as only being an indication of low amount of cancer tissue in some samples 
and hence showing a gene expression pattern similar to that of normal mammary tissue and 
immune cells. Therefore his group is usually not included among the main subtypes (122).  
Luminal A Luminal B HER2 Basal 
ERα+ and/or PR+ ERα+ and/or PR+ ERα- ERα- and PR- 
HER2 - HER2+/- HER2+ HER2- 
Low Ki67 High Ki67 Usually high Ki67  Usually high Ki67 
Table 2. Different tumor characteristics for estrogen receptor (ER), progesterone receptor (PR), HER2 
and proliferation marker Ki67 within the established intrinsic subtypes. The Normal-like have been 
omitted. Adapted from Norum et al. 2014 (123). 
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The intrinsic subtypes have been linked to differences in incidence, survival rates and also 
response to treatment (121,122,124). Later studies have refined and shortened the list of 
genes in the subtype analysis. Today only 50 genes are necessary in the analysis, the so-called 
PAM50 classification (125). First in mouse models and then using larger groups of patients, 
less common subtypes such as the Claudin-low have been identified (66,123). The Claudin-
low subtype seems to show similarities to mammary stem cells and be enriched of 
CD44+/CD24- cells (126,127). Others have divided the Luminal subtypes into smaller sub-
groups (122). The number of genes included in the subtype analysis is now small enough to 
be feasibly analyzed by qPCR instead of DNA microarrays. This opens up the possibility to 
use archived materials from FFPE samples and also to be performed at lower cost (125). 
Many studies have instead used IHC analysis on the routine pathological markers, ER, PR, 
Ki67, and HER2, as surrogate markers for gene expression analysis. This has been seen as a 
cheaper and more accessible method. Albeit, several studies have shown that these two 
different methods are not equivalent and many tumors are therefore classified differently 
(122). 
1.5 ESTROGEN AND ESTROGEN RECEPTORS  
1.5.1 Estrogen receptors 
The estrogen receptors belong to the nuclear receptor superfamily, which consists of as many 
as 48 different members (128). Several of the nuclear receptors still have unknown function 
or unknown ligand; these are known as orphan receptors (129). The nuclear receptors show 
large structural similarities, with six distinct domains (129), indicating that the receptors have 
originated from a common ancestor and later evolved into several types with different 
physiological functions. Nuclear receptors are ligand activated transcription factors, meaning 
that when activated they alter in the transcription of genes (130). As previously briefly 
described, there are two main estrogen receptors subtypes (figure 8). The first one was 
discovered in the late 1950s, later named estrogen receptor alpha (ERα) (131), and the 
second in 1996, named estrogen receptor beta (ERβ) (132). Both ERα and ERβ are normally 
expressed in mammary tissue (133,134).  
The gene for ERα, ESR1, is located on the large arm of chromosome 6 and gives rise to a 
full-length protein of 595 amino acids. There are several variants of ERα, resulting from 
alternative splicing of the transcript, the functions of these are less well understood than of 
the full-length protein (134).  
The ERβ gene, ESR2, is located on chromosome 14 and encodes a 530 amino acid long full-
length protein, known as ERβ1 (135). There are 5 known major transcriptional isoforms of 
ERβ, most of them with truncated C-terminal (10). The best studied is ERβ2, also known as 
ERβcx (136). ERβcx has no ability to bind ligand and therefore has no direct transcriptional 
activity. Instead, ERβcx is thought to mainly form heterodimers when expressed together 
with ERα leading to proteasomal degradation (137). However, ERβcx have also been shown 
to form dimers with ERβ1 (138).    
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Figure 8. Schematic structure of ERα and ERβ and their splice variants. The domains are shown in 
different colors. Percentage denotes the homology between ERα wild-type and ERβ1. Amino acids 
(aa), activation function 1 (AF1), activation function 2 (AF2), DNA binding domain (DBD, and ligand 
binding domain (LBD). From Thomas and Gustafsson, 2011 (134). Reprinted with permission from 
Nature Publishing Group. 
The overall protein structure is the same for ERα and ERβ. However, there are differences in 
the amino acid sequence resulting in, for example, differences in affinity for specific ligands 
(figure 8) (139). The six structural domains reflect the different functions of the receptor 
named A-F (140). At the N-terminus of the receptor (A/B domains) is the location of the 
ligand independent transcript activation function-1 (AF1) (141). This is also the domain with 
the greatest difference in amino acid sequence, with only 20% homology between ERα and 
ERβ (134). The DNA binding domain (DBD) identifies and bind to DNA sequences known 
as estrogen response elements (EREs) after ligand binding (142). In the DBD region there is 
also a dimerization box important for the dimerization of the receptors (142). The hinge 
region (D domain) is responsible for much of the structural flexibility, but also contain the 
nuclear localization signal (143). Closer to the C-terminus is the location of the ligand-
binding domain (LBD) that also contains the ligand binging pocket (144). Next to the C-
terminus is the ligand dependent transcript activation function-2 (AF2) (145), together with a 
second nuclear location signal (E/F domains) (146).  
1.5.2 Estrogen signaling 
The endogenous ligands of estrogen receptors are the female sex hormones. 17β-estradiol 
(E2) is the most prevalent in premenopausal women and is mainly produced in the ovaries 
(147). E2 has the same affinity for ERα and ERβ and causes transcriptional activation. Other 
estrogens such as Estrone (E1) are more predominant in postmenopausal women and Estriol 
 20 
(E3) in pregnant women (148). The main mode of action is the same for the two ERs; after 
binding its ligand in the cytoplasm two receptors will dimerize and translocate into the 
nucleus where it will activate or repress the transcription of genes (134). Other modes of 
action have also been suggested such as activation by phosphorylation, described below 
(149,150). When ligands bind to the LBD, conformational changes in the structure of the 
receptors occur and facilitate dimerization (134). The receptors can be of either the same 
type, so called homodimerization (ERα/ERα or ERβ/ERβ), or of different types, known as 
heterodimerization (ERα/ERβ) (151). Different ligands lead to different conformational 
changes (152). This facilitates the recruitment of either co-activators or co-repressors, 
resulting in differences in the response. Depending on the availability of co-activators and co-
repressors in different cells and tissues, the effect of the same ligands can differ (153). This 
has been shown in a tamoxifen resistance model where the co-repressors N-CoR and SMRT 
were downregulated and making the cells unable to be repressed by tamoxifen (154). On the 
other hand, co-activators of ERs are often over expressed in breast cancer (155).  
Phosphorylation of ERα and ERβ has been shown to activate the receptors independent of 
estrogen binding. There are several known phosphorylation sites on ERα. For example, 
mTOR, MAPK and epidermal growth factor pathways, were able to phosphorylate ERα and 
lead to changes in the expression of ER target genes (156). This mechanism has also been 
linked to poor response of tamoxifen treatment and worse prognosis (149). Phosphorylation 
of ERβ is less well studied, although, in one study has suggested that phosphorylation is 
associated with better breast cancer prognosis (150).        
1.5.3 ERα in breast cancer 
For a long time ERα has been known to play a vital role in breast cancer. As early as 1896, 
Beatson could show that oophorectomy reduced the disease burden in young women with 
advanced breast cancer (157). Data from observational studies point towards lifetime 
estrogen exposure increasing the risk of developing breast cancer (158). For instance, early 
menarche and late menopause increase the risk of breast cancer (159). The increased risk is 
believed to mainly derive from an ERα mediated increase in proliferation and anti-apoptotic 
effects of estrogen on the mammary tissue (160). The use of hormone replacement therapy 
(HRT) have in large studies been associated with increased risk of developing breast cancer, 
both in randomized controlled trials and observational studies (161,162). The risk seemed to 
diminish after the treatment ended (162). However, using a different regimen (Estrogen 
alone) of HRT have yielded opposite results (161). Furthermore, HRT has been association 
with reduced risk of coronary heart disease when give to women with recent menopause 
(163). Today, it is considered that the benefit of symptom relief of HRT, given less than 5 
years in women with recent menopause, outweighs the risk of breast cancer (164). Increased 
body mass index (BMI), which leads to higher serum estrogen levels, has been associated 
with increased risk of breast cancer in postmenopausal women (165). On the other hand, 
treatment with tamoxifen in women with ERα positive primary breast cancer leads to a 
decreased risk of developing contralateral breast cancer in the healthy breast (166). This 
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indicates that antagonizing ERα reduces the risk of developing breast cancer. However, this 
effect was not seen in women with ER negative primary tumors (166), indicating that 
estrogens are more important in some women for cancer development.  
1.5.4 ERβ in breast cancer 
Since the discovery of ERβ, its role in breast cancer has been under scrutiny and many 
studies have examined ERβ1 both in vitro and in vivo (167). For a long time, endogenous 
expression of ERβ1 was not believed to exist in breast cancer cell lines. However, recent 
studies have indicated the opposite, although generally the expression is low (168,169). 
Using overexpression in cell lines, ERβ1 has been shown to be anti-proliferative and function 
as a dominant negative regulator of ERα function (170-172). ERβ1 has also been suggested 
to have an anti-angiogenic role by decreasing the levels of PDGFβ (173). In addition a 
reduction of EMT and invasiveness have been shown, which was thought to occur through 
up-regulation of E-cadherin (174). In human tumor samples, ERβ1 and ERα show high 
degree of co-expression (175). ERβ1 is also less frequently expressed in invasive- compared 
to pre-invasive tumors (176,177).  
Much of the in vitro data points towards ERβ1 having a protective role against breast cancer 
development, data from prognostic studies on patients show inconsistent results (167). 
Several studies have suggested an association of ERβ1 with favorable prognostic variables, 
such as longer disease free- and overall survival, smaller tumor size, fewer lymph node 
metastasis, lower grade, and improved tamoxifen response (178-182). Other studies have 
failed to show such a correlation (183,184). One study has even suggested an association 
between ERβ1 expression and worse outcome in node positive patients (185). The 
inconsistencies may be explained by a combination of factors, such as the use of different 
antibodies in different studies may result in differences in detection of one or several of the 
ERβ isoforms. Thus steps towards using well-validated commercial antibodies have been 
taken (186). Furthermore, the differences in grading systems could also affect the results 
(167). In addition, use of tissue micro arrays (TMA) in some studies could sometimes lead to 
loss of prognostic power. Mainly due to only a small area of the tumor being analyzed and 
therefore heterogeneous expression patterns may be missed. Expression of ERβ1 has been 
described in both the nucleus and the cytoplasm of breast cancer cells, subcellular localization 
have been taken into consideration by some of the studies but not all (182,187). The splice 
variant ERβcx is also commonly expressed in breast cancer tumors, however, it has been less 
well studied and its role is even less clearly understood than ERβ1(167).                       
1.6 DYSLEXIA 1 CANDIDATE 1 IN BREAST CANCER 
Dyslexia 1 candidate 1 (DYX1C1) was the first candidate gene linked to the 
neurodevelopmental disorder dyslexia (188,189). DYX1C1 has been shown to regulate both 
ERα and ERβ1 through proteasomal degradation and form protein complexes together (190). 
Estrogen has been shown to also regulate DYX1C1 transcription (191). Other main functions 
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of DYX1C1 are believed to be in cellular migration and cilia formation and function (192-
194). DYX1C1 overexpression has been shown in malignant breast tumors (195). Higher 
expression has also been shown in several invasive tumor types, including breast cancer, 
compared to normal tissue (196). Other genes associated to dyslexia, such as DCDC2 and 
ROBO1, have also been linked with cancer. DCDC2 has been shown in prostate cancer and to 
be associated with poor prognosis and increased cell motility (197). ROBO1 has been 
coupled to increased migration in breast and several other cancers (198,199). In conclusion, 
the dyslexia candidate genes are an interesting group of genes with regard to their possible 
oncogenic potential, especially because of their role in cellular migration and ER regulation. 
1.7 BREAST CANCER TREATMENT 
While the incidence has increased in the Nordic countries during the last century, mainly due 
to changes in reproductive patterns and nutrition (200), the risk of dying when diagnosed 
with breast cancer has slowly decreased (figure 9) (200). Today the 5-year survival is almost 
90% in Sweden in some age groups, mainly due to improvements in early detection and 
adjuvant treatment (200,201). There are five different categories of treatment; surgery, 
chemo-, radio-, endocrine- and targeted therapy (202).   
 
Figure 9. Incidence and mortality in the Nordic countries. The incidence of breast cancer has steadily 
risen (red solid line, dotted line represents trend). The mortality has slowly decreased (green solid line, 
dotted line represents trend). Age standardized rate per 100000 persons per year for the Nordic 
countries. Standard age structure from 2000 in the Nordic countries. From NORCAN (203).    
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1.7.1 Surgery 
Surgery is considered the main pillar of breast cancer treatment and cures a majority of the 
patients. On small tumors, both total and partial mastectomy surgical techniques are 
considered equally efficient in preventing local recurrences and distant metastasis, when 
combined with radiotherapy (204,205). Presently, the sentinel lymph node (SLN) biopsy 
surgical technique is used routinely in women with clinically negative lymph node status 
(88). It is considered effective in staging the patients, with less co-morbidity than axillar 
dissection (87,206). The sensitivity of finding lymph node metastasis using frozen sectioning 
and staining during surgery is 75-80% (207).  
1.7.2 Radiotherapy 
A meta-analysis of postoperative radiotherapy has shown that it reduces the risk of local 
relapses and improves the survival of the patients undergoing either breast preserving surgery 
or total mastectomy (208,209). The benefit of radiotherapy is most evident in women with 
higher risk of recurrence, specified as a recurrence risk of 20% over 10 years (210). However, 
radiotherapy is associated with increased morbidity, such as reduced lung function, lymph-
edema of the arm, and rashes to the breast and skin (211,212). Radiotherapy is given to breast 
cancer patients in repeated small doses to reduce these side effects (213).  
1.7.3 Endocrine treatment 
Endocrine treatment antagonizing ERα or the production of estrogens is recommended to all 
women with ERα positive tumors (202). Tamoxifen functions through selective modulation 
of ER activation, in breast tissue it works as a partial antagonist (214). Treatment with 
tamoxifen is effective in reducing the risk of recurrence (215). It also improves the overall 
survival by almost 50% and breast cancer specific survival by one third during the first 5 
years (94). Prolonging the treatment to 10 years has shown even better results (94).  
Aromatase inhibitors (AI), block the conversion of androgens into estrogens by the aromatase 
enzyme in tissues where it is expressed (216,217). Aromatase has been shown to be 
upregulated in breast cancer (218). The use of AI is slightly more efficient than tamoxifen in 
preventing recurrences (219). However, AI is only used in postmenopausal women since it, 
because of biological feedback, does not inhibit estradiol production in the ovaries in 
premenopausal women (220). The side effects of AI is coupled to higher risk of osteoporosis 
than tamoxifen, but lower risk of thromboembolic events (221).  
Some trials have used sequential treatment of first tamoxifen and then AI or vice versa. 
Studies are still ongoing and the optimal order and duration for endocrine treatment is still not 
known (202). Although the anti-estrogen treatment is efficient in many women, some 
develop relapse during ongoing tamoxifen treatment. Several mechanisms have been 
proposed (30). One is believed to be phosphorylation of ERα resulting in ligand independent 
activation (156). Another mechanism for acquiring resistance has been through 
downregulation of ERα leading to loss of estrogen dependence (222), this is thought to occur 
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in 20% of the tumors (223). Also changes in cofactor levels have been shown (224). 
Increased expression of the truncated splice variant ERα-36, which has been shown to be 
located on the plasma membrane and in the cytoplasm, and be associated with tamoxifen 
resistance (225). Gain of function mutations discovered in ERα, leading to constitutional 
activation, has also been involved in the resistance to anti-estrogen treatment (226). 
Other challenges regarding the use of anti-estrogen treatment is to identify the patients with 
ERα positive tumors that will not benefit from the treatment. Methods of pre-evaluating the 
benefit of receiving chemotherapy have been developed. The so-called 21-gene recurrence 
score is one of these (227). Identifying similar recurrence score for giving anti-estrogen 
treatment or not would be beneficial to many women. Although endocrine treatment is 
efficient, a obstacle is treatment compliance. As many as 31% of the women did not follow 
the treatment recommendation (228). The main reasons are usually due to of adverse side 
effects (229). 
1.7.4 Chemotherapy 
Cytostatic drugs are only given to women with high risk of relapse, mainly because of the 
risk of severe somatic side effects, such as bone marrow suppression (230). Also the socio-
psychological side effects, for example hair loss, can be very burdensome (230). 
Chemotherapy efficiently reduce the risk of mortality and are usually given in combinations 
of several drugs (231). There are several types of chemotherapy, the most common 
combinations in breast cancer are CMF (cyclophosphamide, methotrexate and fluorouracil), 
FEC (epirubicin, cyclophosphamide and fluorouracil), FAC (fluorouracil, doxorubicin 
(adriamycin) and cyclophosphamide), AC (doxorubicin (adriamycin) and cyclophosphamide) 
and EC (epirubicin and cyclophosphamide) (232). These target vital elements in dividing 
cells thus inhibiting proliferation and leading to apoptosis, therefore they are more effective 
in highly proliferating tumors (233). The relative risk reduction when giving chemotherapy 
has been reported between 22-36% depending on the drugs used and the severity of the 
patients disease (232).  
Neoadjuvant treatment using chemotherapy, together or without anti-HER2 treatment, is less 
common in Sweden and given mostly to patients with locally advanced tumors (202). 
However, neoadjuvant chemotherapy has in resent years been shown to be as efficient as 
adjuvant treatment on large tumors, therefore the use may further increase (234-236). 
1.7.5 Targeted therapy 
Targeted therapies are the most recent addition to the treatment options available in breast 
cancer. In the middle of the 1990’s the monoclonal antibody trastuzumab, targeting the HER2 
receptor, became available (237). Trastuzumab is a monoclonal antibody that binds to HER2 
present on the cell membrane. Several mechanisms of actions have been shown. Among them 
downregulation and internalization of HER2, increased antigen-dependent cellular 
cytotoxicity, cell cycle arrest, induction of apoptosis, and reduced angiogenesis (238,239). 
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When used, mortality has been shown to be reduced in women with amplified HER2, in both 
metastatic and primary disease (240,241). Given together with chemotherapy it reduced the 
relative risk of mortality with as much as 34% (242). However, some women develop heart 
failure as a side effect of the treatment, thus the function of the left ventricle is examined both 
before and during the treatment with trastuzumab (242). Other drugs targeting HER2 have 
more recently become available, for example pertuzumab which inhibits receptor 
dimerization (243). HER2 overexpression can also be targeted by the small molecule 
lapatinib which inhibits the tyrosine kinase function of the receptor (244). 
Other targeted therapies, such as anti-angiogenic antibodies targeting VEGF, have shown to 
be efficient in advanced lung and colon cancer (245,246). However, no difference in 
recurrence rate or survival was seen when used together with chemotherapy in breast cancer 
negative for ERα, PR and HER2 (247). In ERα positive tumors, inhibition of mTOR using 
everolimus has shown promising results (248). The mTOR/Akt/PI3K pathway has been 
implicated in resistance to tamoxifen treatment (249). Thus, inhibiting mTOR, which is a 
downstream enzyme in the pathway has induced apoptosis in cells deprived of estrogen 
(250).   
1.8 BREAST CANCER HEREDITY 
Most breast cancers are considered to be sporadic. These arise because of stochastic events 
during cellular replication, where no specific genetic or environmental cause or risk factor is 
known (251). Nevertheless, there is a hereditary component in breast cancer. Both 
polygenetic risk alleles with slight increases in the risk, and monogenetic hereditary breast 
cancer syndromes have been discovered (252).  
Genes associated with risk of developing breast cancers can be divided into high, moderate 
and low penetrance genes. The high penetrance genes are rare in the population while low 
penetrance genes are common (252). In total, the high penetrance genes are believed to be 
responsible for around 25% of all hereditary breast cancer, meaning that the rest is caused by 
medium and low penetrance genes (253). 
1.8.1 High and medium penetrance genes 
There are several identified high penetrance genes known to cause breast cancer; the two 
most prevalent are BRCA1 and BRCA2. They are believed to cause around 5% of all breast 
cancer cases and around 15 % of all hereditary breast cancers (254). Other genes responsible 
for familiar breast cancer, such as PTEN, TP53 and CDH1, are both less common in the 
population and have lower penetrance compared to BRCA1 and BRCA2 (252). A meta-
analyses has reported a cumulative risk of 57% for BRAC1 carriers and 49% for BRCA2 
carriers of developing breast cancer at the age of 70 (255). Many women who are known 
carriers therefore undergo prophylactic mastectomy, which has been shown to reduce the risk 
of developing breast cancer (256).  
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There is also a group of medium penetrance genes that approximately doubles the lifetime 
risk of developing breast cancers (252). Because they are relatively rare and have only 
moderate increase in risk, they are less clinically relevant. It has been estimated that these 
genes contribute with less than 3% of the hereditary relative risk (257). However, it is likely 
that more medium penetrance genes will be discovered (252).  
1.8.2 Low penetrance genes 
Low penetrance genes, which are common in the population, have mainly been discovered 
through genome wide association studies (GWAS) (252,258). Approximately 30 GWAS 
have been carried out on breast cancers patients (259). After the latest large GWAS, which 
was published in 2013, 41 novel loci were added to the 27 loci that had already been 
identified (260). Together they explain only a total of 14% of the hereditary risk of breast 
cancer, since each locus only contributes with a small increase in risk (260). Of the novel loci 
discovered the highest odds ratio was 1.26 and together the 41 new loci explained only 5% of 
hereditary risk. The authors therefore concluded that there are several thousands of 
undiscovered loci that contribute to the hereditary risk in breast cancer (260). Much of the 
unexplained hereditary risk is thought to be explained these by low penetrance genes  (261), 
together with additional low frequent high penetrance genes, structural differences, gene-gene 
interactions and gene-environment interactions (262).  
For most of the risk loci the mechanisms of the increased risk are unknown (263). However, 
there are some exceptions e.g. FGFR2 and MAP-kinase. FGFR2 is a member of the tyrosine 
kinase receptor family, which induces cell growth, proliferation, angiogenesis and cell 
motility (264). The MAP3K1 gene that encodes the MAP-kinase protein is important in the 
MAP-kinase signaling pathway and is associated with HER2 signaling (264). 
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2 AIMS OF THE THESIS 
 
The general aim of the thesis was to find and evaluate novel and recently discovered breast 
cancer biomarkers to use for prognostication and later potential targets for treatment, focusing 
on estrogen receptors, DYX1C1 and stem cells. 
Aim of paper I - Investigate the dyslexia susceptibility gene DYX1C1 as a potential breast 
cancer biomarker and its role as a prognostic biomarker in women diagnosed with local 
breast cancer. 
Aim of paper II – evaluate the correlation of immunocytochemistry and 
immunohistochemistry on expression pattern of ERα, progesterone receptor and Ki67 in fine-
needle aspirations and surgical resections from the same patients. 
Aim of paper III – examine the prognostic role of ERβ1 and ERβcx (ERβ2) in patients with 
primary breast cancer who had undergone sentinel lymph node biopsy surgery.       
Aim of paper IV – examine the mutational spectra of breast cancer stem cells compared to 
the bulk tumor/non-stem cells, using next generation sequencing to elucidate the origin of 
breast cancer stem cells. 
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3 MATERIALS AND METHODS 
3.1 PATIENT COHORTS 
3.1.1 Uppsala cohort 
The Uppsala breast cancer cohort, used in study 1, consists of altogether 315 patients 
diagnosed with invasive breast cancer in Uppsala County between 1987 and 1989 (265). This 
represents 65% of all patients diagnosed with breast cancer at that time period in Uppsala. 
The clinical data and pathological characteristics of the tumors were collected from the 
patients’ records (265). Using registries, follow up has been updated several times by 
examining the survival status of the patients together with the cause of death. Global gene 
expression analysis was performed using Affymetrix microarray chips on 260 of the patients 
within the cohort. The analysis was performed on all the patients which had sufficient and 
high enough quality mRNA(265). The tumors were then classified into the intrinsic subtypes 
described earlier. Due to the construction of TMAs from the original formalin fixed paraffin 
embedded (FFPE) tumor tissues, the cohort can still today be used to examine the expression 
levels of potential novel cancer biomarkers using immunohistochemistry (IHC) techniques. 
3.1.2 Stockholm cohort 
The Stockholm breast cancer cohort, used in study 1, consists of altogether 524 patients with 
surgically removed invasive breast cancer (266). The inclusion dates were January 1st 1994 to 
December 31st 1996. 280 patients had available tumor tissue. Clinical and pathological data 
for tumor size, lymph node status, hormone receptor status, treatment, date and site of relapse 
and cause of death, were collected from the Stockholm-Gotland breast cancer registry (266). 
The histological grade was re-examined by an experienced pathologist. Of 280 tumors, 159 
were examined using global gene expression microarray chips from Affymetrix. Reasons for 
exclusion, from the gene expression analysis were lack of available frozen tumor tissue, 
emigration abroad or refused to participate, low quality or amount of the extracted RNA, or 
that the patient had received neoadjuvant therapy (266). The patients excluded because of 
lack of frozen tissue had on average smaller tumor size, fewer affected lymph nodes and less 
recurrences. However, the patients excluded due to other reasons did not differ from the 
patients included in on the microarray analysis (266).  
3.1.3 CHARES cohort        
The CHARES cohort, used in study 1, is a population-based case-control study of 3345 
women diagnosed in with invasive breast cancer between October 1st 1993 and March 31st 
1995 in Sweden. Controls were frequency-matched to the age structure of the cases (267). 
Out of these women, 61 cases were randomly selected for RNA extraction and PCR analysis. 
77% of the selected cases were positive for ERα expression.  
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3.1.4 Immunochemistry concordance cohort 
The immunochemistry concordance cohort, used in study 2, consists of all patients diagnosed 
with invasive ductal or lobular breast cancer at Karolinska university hospital during 2011. 
Altogether 454 patients were identified. Patients who had received neoadjuvant 
chemotherapy, had not undergone fine-needle aspiration (FNA) or had longer then 100 days 
between FNA and surgical removal were excluded, resulting in 346 patients. Pathological 
data was retrospectively extracted from the patient’s medical records. However, biomarker 
analysis was not performed on FNA in all patients, thus data on for ERα was available on 
133 patients, PR on 80 patients, and Ki67 on 131 patients.      
3.1.5 Sentinel node cohort 
The Sentinel node patient cohort, used in study 3, was expanded from a part of a large study 
with the aim to investigate the efficacy and safety when introducing the sentinel lymph node 
biopsy technique in Sweden (268). Patients operated using the sentinel lymph node biopsy 
technique in Stockholm between January 1st  2001 and December 31st 2006, with available 
tumor tissue, were included. In the end the cohort consisted of 340 patients. All included 
patients had clinically negative axilla. About half of them had lymph node metastasis. These 
were either discovered by the pathologist using frozen sections or later after paraffin 
embedding and cytokeratin staining. Clinicopathological characteristics, such as size of the 
tumor, treatment, histological grade, HER2 overexpression, time of follow-up, recurrences 
and cause of death, were collected from the patient records.  
3.2 BIOLOGICAL SAMPLES 
3.2.1 Formalin-fixed paraffin embedded tumor tissues 
An invaluable source of materials in the field of oncology comes from the archives of 
formalin fixed paraffin embedded (FFPE) tissue blocks. After the surgical removal of a breast 
tumor, the tissue is then placed in 4% formaldehyde for up to 72 hours. It is then cut into 
smaller pieces and embedded in paraffin. The paraffin embedded tissue blocks can be cut into 
thin sections and mounted on a glass slide. These are later stained and used in the routine 
pathological examination. Most clinical pathology units save the remaining FFPE blocks after 
the routine clinical examinations to be able to re-analyze or perform new staining in the case 
of a recurrence. In addition, many of these FFPE collections are often available for research 
purpose. Commonly they are used to examine the expression of proteins within the tumor 
using methods such as immunohistochemistry (IHC) or immunofluorescence (IF). The 
development of next generation sequencing (NGS) techniques and refinement of global gene 
expression arrays have opened up these archives of tumors to be examined using modern 
DNA sequencing and RNA expression analysis. The benefits using these FFPE collections 
are the long follow-up time and large number of tumors available, while the drawbacks are 
the lower quality of the RNA and DNA that can be extracted from the FFPE samples.  
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3.2.2 Scrapings and primary cultures 
Snap fresh-frozen pieces of tumor tissue are the most widely used method for research 
biobanking today. It is suitable technique to obtain high quality tumor material for later RNA 
and DNA extraction. However, there are several problems with the method. For example, 
there is a risk of potentially removing a section from the tumor that will not be analyzed 
during pathological examination. This may in the worst case lead to that the wrong diagnosis 
or treatment is given. This is especially evident in small tumors where the removed piece for 
biobanking is relatively large to that of a bigger tumor. This results in that many of the 
smaller tumors are not included in the biobank, thus introducing selection bias (269).  
We have introduced a novel method of collecting tumor cells for biobanking without the need 
to remove a piece of the tumor (269). Cutting the tumor in half and using a scalpel to scrape 
3-10 times around the surface of the tumor cells can be collected. The yield is enough for 
several cell- and molecular biology methods such as RT-qPCR of mRNA, FACS sorting, IF 
and cytological staining, DNA extraction for pyrosequencing, and cells for cultivation. The 
material from the scrapings can be stored in liquid nitrogen or be used for analysis directly. 
This method has the potential to increase the number of patients with tumors suitable for 
biobanking. We have estimated that the inclusion of patients could increase from around 60% 
to 85%, with little increase in workload for the pathologist (269).  
Breast cancer stem cells can be enriched from these scrapings. By cultivation in serum free 
medium in non-adherent flasks these can be enriched in a few days (269). These cells grow in 
free-floating cell clusters (mammospheres), as have been described earlier. Cells without 
stem cell capabilities are not able to survive in the non-adherent, serum free conditions, and 
perish. This is a method of selecting cells with stem cell like capabilities according to their 
functionality, rather than surface markers.   
3.3 PROTEIN EVALUATION 
3.3.1 Immunohistochemistry and Immunocytochemistry 
The proteins within the cell are vital for the biochemical reactions, structure and survival of 
the cell. The translation of different mRNA into proteins governs the function of that 
particular cell. In cancer, the regulation of the protein expression is often compromised. Over- 
or under-expression of different proteins is common in tumors. In oncological research it is 
therefore essential to investigate and compare the expression of different proteins within a 
tumor. Protein expression can be examined through immunohistochemistry (IHC) and 
immunocytochemistry (ICC) (270). IHC and ICC are methodically very similar, however 
IHC is performed on histological (tissue) sections whereas ICC is performed cytological 
(cell) material. Differences exist mainly in the preparation and fixation of the material. Both 
methods take advantage of the ability of the adaptive immune system to produce specific 
antibodies that bind to different proteins. This is then coupled to basic biochemical reactions 
to detect the presence of a specific protein. The cells of the adaptive immune system can be 
instructed to produce antibodies against any protein within the human cell. For research this 
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is done in two principally different ways. Either through injecting the targeted protein into an 
animal host where it will be identified as foreign and produce antibodies. The antibodies 
produced will target several structures of the protein of interest, yielding polyclonal 
antibodies. The second method instead uses immortalized B-cells in vitro. By introducing a 
gene fragment corresponding to a specific epitope into the B-cells, they start producing 
antibodies. These monoclonal antibodies target only one specific region of the protein of 
interest. The antibodies that are central in the IHC and ICC methods are also one of their 
main weaknesses. There is always a risk that the antibodies are not specific, but may also 
cross-react with other proteins, resulting in false positive results (271). Raising monoclonal 
antibodies against regions of the proteins that are unique can reduce this risk.  
Several tests can be performed to examine the specificity of the antibodies, such as antigen 
blocking, where the antibody is saturated with antigen.  Furthermore, one can also look for 
diminished staining of the antibody in a culture or tissue where the protein has been knocked 
out. Other biochemical methods, such as Western blotting, are commonly used for validation. 
If a protein is detected with the predicted molecular weight, this strengthens the evidence of 
the specificity of the antibody. An advantage of IHC is the additional spatial information of 
where or in which type of cells within a tumor a protein is expressed. This is not possible 
with other methods such as PCR or Western blotting. Therefore using IHC one can be more 
certain that the protein is present within the cells of interest, and not in the stroma or immune 
cells within the tumor. 
One of the main challenges of IHC and ICC is how to reliantly quantify the staining of your 
protein of interest, especially when it is important to be able to compare the expression 
between different tumors. Examination of the sections has traditionally been by microscope 
and manual grading of the expression. The arbitrary grading system should also be suitable to 
the protein of interest. To reduce the observer bias and improve the reproducibility of the 
scoring, at least two independent observers often score the same samples. However, this is 
time consuming and do not completely remove observational bias. In the recent decade the 
increase in computer power has made it possible for digital image analysis programs to 
digitally quantify the expression of a protein. These programs have the potential to improve 
the reproducibility of the scoring significantly (272,273). Still, the image analysis software is 
not perfect in being able to distinguish all normal cells from cancer cells. Nor can it detect 
and count all cells within an area. The shape of a cancer cell can be very different, which 
sometimes makes it hard for the program to identify. Therefore, for some analysis programs 
there is a need to manually annotate the area of interest, e.g. the invasive cancer areas. Also it 
is important to review the detection rate of cells and examine the output of the image analysis 
software.        
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3.4 DNA AND RNA EVALUATION 
3.4.1 Polymerase chain reaction 
One of the most commonly used methods within molecular biology is the polymerase chain 
reaction (PCR) developed in the 1980’s and later rewarded the a Nobel Prize in Chemistry 
(274). PCR is a fast and efficient method of amplifying and quantifying DNA and mRNA 
from different sources. Through repeated cycles, heat stable polymerases can copy a 
particular sequence of nucleotides in vitro in a short time span. The output DNA can then be 
used as input material in other biochemical methods. It can also be quantified to compare the 
relative or absolute amount of mRNA within a cell line. The main advantage of using PCR 
for the quantification of the expression of a gene is the robustness and reproducibility of the 
method. Using modern PCR with rapid thermal cycling and 96-well plates, a few hundred of 
samples or genes can be processed daily.       
3.4.2 DNA Microarrays  
The development of DNA microarrays before the turn of the last century started the era of 
global gene expression profiling. DNA microarrays are used to compare global changes in 
expression patterns between different tumors, but can also be used to compare differences in 
expression profiles with different treatments of cancer cells lines. The main principle of DNA 
microarrays is that a sample of DNA is allowed to hybridize to a single stranded 
complementary sequence of DNA corresponding to a gene transcript. The complementary 
DNA sequence is usually attached to a glass slide, depending on the manufacturer. Each 
potential gene transcript in the human cell has a corresponding complementary DNA 
sequence on the microarray chip. These DNA sequences are usually between 20 to 60 
nucleotides long. If the gene is expressed or DNA present in a sample, it will hybridize to its 
complementary DNA sequence on the array and be detected. Detection is usually performed 
by fluorescently labeling the input DNA sample. Quantification is achieved since the 
intensity of the fluorescence is directly correlated to the number of mRNA molecules of that 
specific transcript in the input sample. Each complementary oligonucleotide is spotted to a 
specific location on the microarray. Thus, when scanning the fluorescently labeled array, each 
spot correlates to a specific transcript of a gene and each individual gene. 
3.4.3 DNA sequencing 
Since the discovery that DNA harbored the genetic code, many methods of DNA sequencing 
have been developed. In the last 10 years a rapid progress of the sequencing methods has 
taken place. This has resulted in an increase in speed, and at the same time, lowered the costs 
of sequencing. Modern massive parallel sequencing methods have revolutionized the research 
community and have also slowly begun to be introduced into the clinical setting. The 
sequencing is run in parallel to increases the speed (275). However, the reeds are shorter than 
traditional sequencing techniques (275). The exome, which encompasses the protein coding 
areas, only consists of only 1-2% of the complete human genome. Whole exome sequencing 
can therefore be more cost effective than sequencing of the whole genome (276). 
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Consequently, when only the exome is targeted, it can be sequenced with greater depth to 
uncover rare mutations within the tumors (277). During the preparation for exome 
sequencing, the exomes can be enriched using several different methods. Enrichment by 
PCR, ligation to magnetic beads, hybridization to complementary sequence or a combination 
of these is common. In study 4, we used a method from NimbleGen that uses hybridization to 
oligo-probes together with bead extraction. 
To be able to reliably call the nucleotide variants that are present only in the tumor, so called 
somatic mutations, DNA from normal cells from the patients also need to be sequenced. The 
reason is to detect the germline nucleotide variants that the patient was born with. We used 
DNA extracted from blood samples from the patients. In parallel with the progress of 
sequencing techniques, several bioinformatics tools have been developed. These were 
specifically designed to aid in the analysis of sequence raw data. Since sequencing is 
performed in parallel, not from start to finish and on short sequences, reads are aligned 
against the reference genome. We used one of the most frequently used called Borrows-
Wheeler Aligner (278). During the sequencing library preparation, PCR is performed on the 
input DNA yielding duplicate sequences. These are usually removed since they do not 
increase the information of the present mutations. Somatic variant callers can be used to 
compare the probability that a detected variant in the sequencing data is a true somatic 
mutation. There are several such tools to detect mutations within the tumors with high 
specificity and sensitivity. This means that they can reliably detect mutations with low allele 
frequency within the tumors (279). The accuracy of massive parallel sequencing is very good. 
However, the vast number of nucleotides examined means that there will be errors in the 
sequencing data (275). A way of decreasing the risk of false positives or false negatives is to 
increase the read depth. However, this will increase the cost. One method to confirm somatic 
mutations is to perform ultra-deep re-sequencing on some selected areas where the mutation 
has been found. Through improved depth, one can confirm or discard interesting mutations 
found in the first step of exome sequencing.     
3.5 STATISTICS 
Several statistical methods and tests have been performed to examine the hypotheses in our 
studies. For example, Student’s T-test, Fisher’s exact test, linear regression and survival 
analysis are a few of the methods used. The parametric Student´s T-test requires that the 
sample is normally distributed. If this assumption is not upheld, non-parametric tests such as 
the Mann-Whitney test can be performed.  
In cancer research, identifying biomarkers that can be used to prognosticate the survival of 
the patients are important. In Sweden personal identification numbers and registries with high 
coverage can be cross-referenced. This makes up an important tool for researchers. Using the 
death registry or examining the electronic medical records of the patients, one can gather 
good quality data on follow-up. This can then be used to examine the prognostic effect of 
novel biomarkers on overall, disease-free or breast cancer-specific survival. In survival 
analysis, not only the event, e.g. death, but also the time until the occurrence of the event is 
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taken into consideration. This means that the effect of a prognostic marker to postpone the 
event can be studied. The Kaplan-Meier estimate can be used to estimate and visualize the 
survival probability. The Cox proportional hazard model is a statistical model to test survival 
differences between different groups of patients and can be used with both categorical and 
continuous explanatory variables. The Cox proportional hazard model yields the rate of an 
event per unit of time over baseline risk. Additional variables can be included in the model to 
control for these and reduce confounding. To withhold the assumptions of the model, enough 
events need to have taken place, this can sometimes be a problem when studying breast 
cancer patients since the survival is usually good, and if the cohort is not large enough the 
number of events can be too low. However, it has shown that only few events are needed if a 
priori hypothesis is present (280). 
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4 RESULTS AND DISCUSSION 
4.1 PAPER I   
“The dyslexia candidate gene DYX1C1 is a potential marker of poor prognosis in breast 
cancer” 
Two studies published in 2009 implicated a role for DYX1C1 as a potential biomarker in 
breast cancer (195,196). However, the studies consisted of few patients and the authors were 
therefore unable to investigate the expression of DYX1C1 among different types of tumors or 
in association with prognosis. Prior these publications, very little was known of the role of 
DYX1C1 in cancer. 
Thus, we examined the mRNA and protein expression of DYX1C1 in three independent 
breast cancer cohorts, in total 535 patients (Uppsala, Stockholm and CHARES cohort). The 
expression was examined against the clinicopathological characteristic and survival of the 
patients. Using data on mRNA expression from qPCR and microarray, we found that 
DYX1C1 was more highly expressed in ERα positive tumors. A similar association was seen 
between DYX1C1 and the progesterone receptor. DYX1C1 was also lower expressed in 
tumors of histological grade 3, compared to grade 1 and 2. Tumors of Basal and HER2-
enriched intrinsic subtypes also had a lower expression than the Luminal A and B subtypes. 
Taken together, our results point towards an association of DYX1C1 mRNA expression with 
less aggressive tumor types.  
When examining the protein expression of DYX1C1 using IHC, in tissue from 10 normal 
breasts we observed high expression of DYX1C1. A majority of the breast cancer tumors also 
expressed DYX1C1 protein. However, 11.3% of the invasive cancers had lost the expression. 
Using a univariate survival model, we also found that loss of DYX1C1 was associated with 
shorter overall patient survival. The association remained significant in a multivariate Cox 
regression model, after adjusting for age at diagnosis, lymph node status, grade, ERα- and 
PR-status. Women with tumors that were DYX1C1 negative had an increased risk of dying, 
with a hazard ratio of 3.44 (95% CI 1.84-6.42). 
The knowledge of DYX1C1 in breast cancer is still limited. Today, only three studies, 
including ours have, been published that examines DYX1C1 as potential biomarker in the 
disease. The functional role of DYX1C1 in breast cancer is even less well studied. In 
dyslexia, DYX1C1 it is believed to be important in ER regulation, cilia formation and 
neuronal migration. Other genes associated to dyslexia such as DCDC2 and ROBO1 have 
been implicated in several cancers, perhaps indicating that this group of proteins has an 
important role in cancer physiology. DYX1C1 has been shown to regulate and be regulated 
by both ERα and ERβ. In fact, the promoter region and 5’-untranslated region of DYX1C1 
contains several half-ERE and AP1-sites which ERs potentially can bind to under the right 
conditions (191). Although speculative, DYX1C1 may function as a regulator of the 
expression or degradation of ERs in breast cancer. Yet, with the limited knowledge about 
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DYX1C1 in breast cancers, it cannot be excluded that the gene is only an innocent bystander. 
Thus, further studies are needed to confirm DYX1C1’s role in breast cancer. 
4.2 PAPER II 
“Low concordance of biomarkers in histopathological and cytological material from breast 
cancer” 
The correct evaluation of biomarkers such as ERα, PR and Ki67 is essential for the correct 
treatment of breast cancer patients. We collected retrospective data from 346 patients of 
paired ICC and IHC evaluation (Immunochemistry concordance cohort). As a step in the 
diagnosis of breast cancer fine-needle aspirations (FNA) are taken from the tumors. These are 
then sometimes stained using ICC for several biomarkers. Although, it is not recommended 
that ICC should be used in the clinical decision making of the treatment of primary breast 
cancers, instead evaluation using IHC is considered gold standard. However, sometimes 
when examining metastatic lesions only FNA and thus ICC, may be available. Consequently, 
it is important that there is a high correlation between ICC and IHC.  
Hence, we compared the correlation of ICC and IHC in ERα, PR and Ki67 evaluation using 
paired samples from the same tumor. In total we had data from both IHC and ICC on 133 
patients for ERα, 80 patients for PR and 131 patients for Ki67. We found that on average, 
ICC evaluation of ERα expression was reported as 10.6 percentage points lower than when 
the same tumor was evaluated using IHC. When comparing positive from negative tumors 
using either 1% or 10% cut-off for ERα, 9.0% or 10.5% of the tumors, respectively, switched 
expression status from negative to positive or positive to negative. Similarly when evaluating 
PR, the expression was on average lower using ICC than IHC, this time by 13.6 percentage 
points. Using a 1% or 10% cut-off to discriminate positive from negative tumors, 7.5% and 
11.3% of the tumors were differently classified, respectively.  
When comparing the scoring of Ki67 expression, the expression was lower by 7.9 percentage 
points by ICC than IHC. Because there is no well-established cut-off for distinguishing 
between high and low proliferating tumors we used two different cut-offs; 14% and 20% 
which had been used by others previously (102). Using the 14% cut-off, 32.8% of the tumors 
changed proliferation classification from low to high or high to low. With a cut-off of 20%, 
29.8% of the tumors were re-classified. We also showed that by adjusting the cut-offs used 
for ICC classification of Ki67 from 14% to 10% and from 20% to 14%, the number of 
patients that were re-classified was slightly decreased. Although, since the scoring of 
individual tumors could be either higher or lower in ICC compared to IHC, modifications of 
the cut-offs did not remove all the re-classification.   
As a step in the routine diagnosis of breast cancer in Sweden, a FNA sample is often 
collected for analysis by a cytologist. Although, it is recommended that all predictive 
biomarkers should be analyzed on histological sections using IHC to ensure high validity, it is 
not unthinkable that ICC evaluations presented may influence decision-making at treatment 
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conferences. On the other hand, for metastatic lesions, ICC from FNA may perhaps be the 
only available source of material and is thus extremely important in the treatment decision.  
We observed both over- and underestimation of ERα, PR and Ki67 when comparing ICC to 
IHC on individual cases, although on average, ICC systemically underclassified all three 
biomarkers. There could be several reasons for this, where one is the difference in the time 
point from when the samples were collected, where the FNA can precede the surgery by 
months. Another reason is that sampling using FNA represents a random small area of the 
tumor compared to the complete tumor evaluation by IHC. This is especially apparent for 
Ki67, since the recommendation is to evaluate the expression in the proliferative hot spots. 
Using ICC it is impossible to know if the sample has been extracted from the hot spot areas. 
In addition differences in fixation and preparation process are common between ICC and IHC 
and have been shown to cause variances in the intensity of staining. This is mainly believed 
to happen through differences in the deterioration rate of the biomarker.  
When evaluating the data, we observed that a disproportional number of the ERα and PR 
grading was located around the cut-offs of 10%. This was seen in both the IHC and ICC 
evaluation, but was more common for ICC. The reason for this may be explained by a will of 
the cytologist and pathologist to not underdiagnose patients. This bias could be introduced 
unconsciously, to not withhold patients from endocrine treatment that is considered both 
efficient and safe. Additionally, it cannot be excluded that since the ICC evaluation is 
followed by an IHC evaluation, which the treatment should be based upon, the need for 
precision of the ICC evaluation decreases. This may also affect the accuracy of the ICC 
evaluation.  
Using novel techniques of liquid and paraffin based ICC it has been shown that better 
concordance with IHC evaluation can be achieved. It is therefore important that pathological 
and cytological labs consider implementing these techniques. Evaluation of the correlation 
between ICC and IHC is important to decrease the variability of breast cancer scoring, 
especially for the diagnosis of metastatic lesions.       
4.3 PAPER III  
“Oestrogen receptor β1 and βcx have divergent roles in roles in breast cancer survival and 
lymph node metastasis”  
The role of ERβ1 in breast cancer has been highly debated. We decided to investigate its 
prognostic significance and association to several clinical characteristics. We used a cohort of 
340 women with local primary breast cancer and clinically negative axilla (The sentinel node 
cohort). We also examined the expression of ERα and ERβcx (ERβ2) in the same cohort. As 
described in other studies (281,282), we could observe that ERα was expressed 
predominantly in older women and in tumors of lower grade. ERβ1 was on the other hand 
equally expressed in patients of all ages and grades. ERβcx positive tumors showed a higher 
risk of having synchronous sentinel lymph node metastasis. However, no such association 
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was seen for either ERα or ERβ1. During the follow-up period, only 36 of the 340 patients 
died, whereof 16 deaths were due to breast cancer. Even with this few events, we found that 
ERα expression was associated to better breast cancer-specific survival. Also ERβ1 positivity 
was associated to both better breast cancer-specific and overall survival, this was not seen for 
ERβcx. The prognostic significance for ERβ1 was especially evident in high-grade tumors 
and in younger patients. Using a multivariable Cox regression model we found that ERβ1 
remained an independent prognostic factor for both overall and breast cancer-specific 
survival. When examining the co-expression of ERα and ERβ1 in regards to the prognosis, 
the worst was seen in ERα and ERβ1 negative patients. Thus, the expression of either ERα or 
ERβ1 or both improved the prognosis.     
There have been varied results among the studies that have examined the role of ERβ in 
breast cancer. The reasons for these could be several. One of them has been the lack of 
validated commercial antibodies, specific for different ERβ subtypes. Through the validation 
work by Dr. Valerie Speirs and her colleagues, the possibility to perform reproducible 
evaluation of ERβ in breast cancer tumors have greatly improved (283). In our study we used 
validated, commercially available antibodies. We also implemented digital image analysis 
software to reduce observer bias and increase the reproducibility of the scoring. Using 
histological sections instead of TMAs we could also reduce the effect of expression 
heterogeneity of the ERs within the tumors.  
Our main finding, that ERβ1 seems to be an independent marker for good prognosis in breast 
cancer, is in accordance with most of the so far published studies (178-182). However, there 
are several studies that have failed to find such a connection (183,184). There is even one 
study that has shown ERβ1 to be a marker of poor prognosis (185). These discrepancies can 
perhaps be explained by differences described above when examining ERβ1 expression. 
Interestingly, we observed high expression ERβ1 and the strongest association to survival in 
the youngest patients and in patients with high-grade tumors. These are two groups that 
usually are considered to have worse prognosis. This may imply that ERβ1 could be used as a 
therapeutic target in these women. There are several compounds with selective affinity of 
ERβ1 over ERα that could be used as potential drugs to target ERβ1.  
The splice variant ERβcx lacks the ability to bind ligand. It is instead thought to regulate the 
levels of ERα and ERβ1. In our study, we could not find any association of ERβcx with 
regard to the survival of the patients. Instead, high expression of ERβcx was associated with 
increased risk of synchronous lymph node metastasis. Since lymph node metastasis is 
considered one of the strongest prognostic risk factors, we would perhaps have observed a 
survival association for ERβcx in a larger cohort with more events.  
The low number of events is also the main limitation of our study. We had 340 patients in our 
cohort, with a median follow-up for breast cancer-specific survival of almost 7 years and 
overall survival of more than 9.5 years. Still, total number of deaths limited the number of 
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sub-analysis that could be performed and the interpretation of these should therefore be 
viewed with some caution. However, we believe that our results may merit routine analysis of 
ERβ1 in breast cancer tumors, especially in younger women with high-grade tumors. This 
could perhaps improve the prognostic capabilities of the pathological examination in these 
patients. To examine if ERβ1 has a predictive role, a prospective study using ERβ1 as an 
indicator for endocrine treatment in a neoadjuvant setting might be promising. 
4.4 PAPER IV   
“Sequencing of breast cancer stem cell populations indicates a dynamic conversation 
between differentiation states in vivo” 
A population of cells with stem cell capabilities can be identified in breast cancer tumors. 
They can be isolated either by their ability to form mammospheres or cell surface markers 
such as ALDH1, CD44 and CD24 (53,61,63). The origin and role of these cells in breast 
cancer tumors have been debated.  
We set out to compare the mutational spectra of isolated breast cancer stem cells to that of the 
cells of the bulk primary tumor or non-stem cells. Our hypothesis was that breast cancer stem 
cells would harbor a higher frequency of the mutations that were most important in early 
tumor development and thus let us identify the so called driver mutations. We used whole 
exome sequencing and bioinformatics tools to identify somatic mutations. Mammosphere 
formation assays, and ALDH1high and CD44+/CD24-/low isolation by FACS were used to 
identify breast cancer stem cells.  We then compared, from the same tumor, the mutations 
found within the isolated stem cells to mutations found in the bulk tumor containing mostly 
differentiated cells. We also compared the stem cells to FACS sorted non-stem cells 
(ALDHlow and CD44-/CD24+/-). The combination of these two are from here on called the 
“bulk tumor/non-stem cells”.  
Contradictory to our hypothesis, the mutations discovered were present in both the stem cells 
and the bulk tumor/non-stem cells at the same frequency. Irrespective of the isolation method 
(mammosphere of FACS) we could show similar overlap of somatic mutations in the stem 
cells and bulk tumor/non-stem cells. Interestingly, the allele frequency of the mutations was 
highly correlated between the stem cells and the bulk tumor/non-stem cells.  
However, a few mutations were unique to either the stem cells or cells of the bulk tumor/non-
stem cells; these were often of low allele frequency. To invastigate that the unique mutations 
were not sequencing errors or missed due to low coverage, we selected 14 mutations sites in 
three different patients and performed ultra-deep amplicon-sequencing. These were either 
unique or shared mutations present in the stem cells or bulk tumor/non-stem cells. This 
allowed us to validate that three of the shared mutations in the original sequencing remained 
shared also using the ultra deep sequencing. The 11 mutations that were either unique to the 
cancer stem cells or to the bulk tumor/non-stem cell were either false positive (four 
mutations), technical artifacts (one mutation) or shared (five mutations). However, one 
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mutation was confirmed to be unique in the cancer stem cells, although at a low allele 
frequency of 5%. Thus, these could originate from a local clone of cells.      
Our results support the theory that breast cancer stem cells are a dynamic phenotype present 
in breast cancer tumors. We could not find evidence that breast cancer stem cells give rise to 
the rest of the tumor through a hierarchal model. If this were the case fewer mutations should 
be found in the stem cells and some mutations should be unique to the bulk tumor/non-stem 
cells. The most complete way of explaining the presence of the same mutations at equal allele 
frequencies in both stem cells and non-stem cell compartments, is by a dynamic transition 
model. This suggests that cells with differentiated phenotype can transform into cells of stem 
cell phenotype and vice versa.  
In one study, no differences were seen in copy number variations of CD44+ cells compared to 
CD24+ in breast cancer cells (284). In a study by Gupta et al., cell lines from Luminal, Basal 
or stem cell subtype origin showed striking transforming capabilities into the other subtypes 
after cultivation (67). This suggests that differentiated breast cancer cells have the capabilities 
to transform into both stem cells and cells of other subtypes. In breast tissue, where the 
sheading of epithelial cells occurs at slower rates, there is more time for differentiated cells to 
become malignant. Therefore all cancer cells do not have to originate from the stem cells. 
This may be the case for breast cancer, where genomic events perhaps can result in a 
differentiated cell to acquire stem cell capabilities. A hierarchal stem cell model may be more 
suitable in cancers were the turn-over rate of the cells are higher, for example in the gut or in 
the bone marrow. In these tissues the time to obtain the vital genomic events to become 
malignant is too short and therefore only can take place in the long-lived stem cells. 
The mechanisms of dynamic stem cell formation have been suggested to be similar to that of 
epithelial-to-mesenchymal transition (EMT). EMT is thought to occur due to epigenetic 
changes, especially DNA hypomethylation (64). Breast cancer stem cells have shown to 
harbor hypomethylation of several transcription factors involved in EMT. Silencing of micro-
RNAs through hypermethylation has also been shown in both EMT and breast cancer stem 
cells (64). Furthermore, overexpression of the transcription factors Twist and Snail, important 
in EMT, in immortalized human mammary epithelial cells increased the mammosphere 
formation (285). In addition treatment using TGFβ have shown to produce both EMT and 
breast stem cells (69).                 
4.5 GENERAL DISCUSSION AND FUTURE PERSPECTIVES 
The treatment of breast cancer has improved drastically in the last 100 years. Today, most 
women who are diagnosed with breast cancer have a good prognosis. However, due to the 
high incidence many women still die of the disease. The increased life expectancy and 
changes in life style means that the incidence of many cancers, among them breast cancer 
have slowly increased. As pointed out by Bert Vogelstein in a recent review, bad luck is one 
of the major risk factors for developing cancer (286). Therefore, complete prevention or 
eradication of all cancers will probably not be possible. Instead, early detection and further 
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improving the treatment will be increasingly important. Identification of novel biomarkers 
and understanding the biological processes of breast cancer development are important early 
steps in later improving the survival. Both ERβ1 and DYX1C1 have the potential to become 
important breast cancer biomarkers or lead to the identification of novel mechanism of breast 
cancer development. In the end they could perhaps become novel targets for treatment. ERβ1 
is especially interesting since it is a receptor and therefore easily can be targeted by selective 
drugs. Whereas studying DYX1C1 may instead lead to better understanding of the properties 
needed for cellular migration and ER regulation. Due to the inconsistencies observed in the 
effect of ERβ1 on survival, the role of ERβ1 in breast cancer is not clearly understood. 
However, the majority of in vitro and in vivo studies points towards a protective role (167). 
The main goal would be to test to treat breast cancer patients with ERβ1 targeting drugs. Still 
today we are far from that goal, since the scientific basis of ERβ1 role in breast cancer needs 
to be strengthen and also the treatment needs to be tested in animal models. 
Fine needle aspirations are a safe and cost efficient method of identifying malignant cells. It 
is also sometimes the only available method of extracting cells from distant metastasis for the 
analysis of biomarkers. This is especially important since studies have shown that the status 
of several biomarker can switch from primary tumor to metastasis lesions (287). 
Nevertheless, it is important for clinicians to understand that results from ICC and IHC are 
not always equivalent, suggesting that some tumors can be wrongly classified as either ERα 
negative or positive, thus resulting in the wrong treatment being given. Instead of performing 
analysis of FNA using ICC, quantification of ERα by RNA-sequencing could perhaps 
increase the reproducibility. We are presently part of a project that intends to evaluate the 
accuracy and efficiency of RNA-sequencing compared to IHC for several of the routine 
biomarkers. Perhaps this can be done for FNA of metastatic lesions as well. 
The role and presence of cancer stem cells in breast cancer are far from settled. Today most 
would agree that there is a subset of breast cancer cells that have increased malignant 
potential. If these should be called stem cells or not is perhaps more a case of semantics. 
Finding a way to target these cells, which seem to have higher resistance to common 
chemotherapy and radiotherapy will become important. The understanding that breast cancer 
stem cells is a phenotypic state rather than a fixed subset of cells leads to the consequence 
that new breast cancer stem cells can be generated from even a small number of differentiated 
breast cancer cells. These cells could therefore result in a relapse if these cells are not 
sufficiently targeted. Hence, finding treatments that are efficiently targeting both subsets of 
cells could perhaps be beneficial for the patients and improve survival. One of the main 
difficulties when studying breast cancer stem cells is the lack of a universal biomarker. The 
identification of such a biomarker would greatly improve the understanding of breast cancer 
stem cells and would be important for the future studies and understanding of these. 
  
 42 
5 ACKNOWLEDGEMENTS 
I wish to acknowledge everybody who have collaborated, helped, or in any way supported 
me during these years. I especially want to thank: 
First and foremost, all the women diagnosed with breast cancer that unselfishly contributed 
their time, a tumor specimen or their disease history to research. Without you the advances in 
in breast cancer treatment would not take place. Thank you!    
My main supervisor Johan Hartman, you have inspired me and showed me that it is 
possible to perform great research even with small amounts of time. I do not understand how 
you are able to produce all the research you do with a large family and work as a pathologist. 
You are one of the most driven persons I have ever met. Thank you for this time together! 
I want to thank my co-supervisor Juha Kere, for always supporting my decision to become a 
medical doctor and for believing in me when I was in need for a research group. You are not 
only a brilliant researcher but also probably the nicest person I have met in the academic 
world.       
Ulf Hannelius, co-supervisor and entrepreneur. You have inspired me a lot during these 
years. Always coming up with new ideas of something that could be made into an interesting 
project. You have repeatedly showed me that research is far from boring.  
Members of the lab at CCK. Ran Ma and GM Karthik, thank you for your endless 
discussions on research in our small office. I admire your research skills, both of you will go 
far if you decide stay in the academic life. Thank you also for giving me a taste of the 
Chinese and Indian culture.  Good luck with your own PhDs!  
Lisa Viberg, I can’t thank you enough for all your help during these years. You have an 
incredible ability to get things done. Whenever I have needed help you have supported me. 
Sussie Agartz, thank you for all the assistance in the lab. Anna-Lena Borg, former lab 
technician, thanks for your help and support.    
Jonas Bergh, thank you for letting me work in your lab even though I wasn’t officially a 
member of your group. Without your generosity this thesis would not have been finished. 
You are a truly inspiring clinician and researcher.  
Jan-Åke Gustafsson, Margaret Warner and Konstantin Yakimchuk, thank you for 
introducing me into the field of breast cancer research.  
Members of the CRiSP Linnaeus center. Especially Per Hall, Henrik Grönberg and Kamila 
Czene for your collaborative efforts and financial support. 
To my collaborators Daniel Klevebring, Linda Lindström, Irma Fredriksson, Jan Frisell, 
Jana de Boniface, Felix Haglund and John Lövrot. Thank you for the efforts you made in 
our studies, it has been inspiring to work with all of you.  
  43 
Past and present members of the Kere lab in Huddinge. Myriam, Isabel, Hans, Tiina, Cilla, 
Lisa, Elo, Lovisa, Ingegerd, Kristiina, Pauliina and Virpi. Although my visits have 
become less frequent, you have always greeted me with smiles and encouragements. Thank 
you for your support during these years. 
The administrative staff at BioNut, Monica, Lena, Marie, Vivian. You have always been 
curious and asking questions about my progression in medical school. Thank you for your 
encouragements and your help.   
To my novel friends Susanne, Adam, Hanna, Peder, Carro, Erik, Helene and Mattias. It 
has been wonderful to get to know you. Thank you for all the dinners, trips to summer- and 
winter-houses and training-rides, runs and camps. I look forward to many more! 
My friends on the bike, Niclas, Ivar and Daniel. I have had such a great time riding (and 
talking about riding) our bikes together. The best way to relax a tired mind is to exercise. 
#tråden 
John and Lars, my closest friends in medical school. It is incredible how fast five years 
seems to pass when most days are filled with laughter. It has been such a great time, you have 
made it so much easier to combine school with research because you make coming too school 
fun every day. I also wish to thank some of my classmates who have shared clinical 
placements, group work and lunches together with me, among them: Kristina, Alexandra, 
Emma, Nils, Martin, Charlotte, Caroline and Markus and many more... I’m looking 
forward to graduating together with you in January.     
To my best friends Pär, Viktor, Mattias and Pontus and their wives and fiancées Sofia, 
Tessan and Maria. Soon we have known for almost half our lives. I always have such a great 
time when we see each other, either at trips, dinners, quiz-nights, exercising or just hanging 
out. I can’t imagine how dull everything would be without you. Looking forward to an 
exciting future.  
To the “Örtqvist” family: Eva and Åke, Thank you for including me into your family. I 
always feel warmly welcome when we are in Åre, on Gotland or just having Sunday dinner 
together. Lisa and Mimmi, for inspiring me on how to be successful in academic, clinical 
and family life. Daniel and Kecke, for all the nice beers and for leading the way on how to 
become a real “Örtqvistare”. Ville, Agnes, Greta and Ellen, it’s been so much fun getting to 
know you, looking forward to see you grow up.          
To my aunt Eva, cousin Carro and Martin and uncle Lasse and Kerstin, to my bonus-
bother Niklas and Malin. It’s always so nice to see you during our family gatherings, and to 
talk about the past present and future. 
My brothers, Daniel, you are as close to being a biological brother as you can be without 
sharing any genes. Your willpower has been an inspiration. Erik, growing up with someone 
so close together in age made us extremely close. It has been so nice to see you develop into 
 44 
the inspiring person you are today. Your positive lifestyle is a motivation for me to also 
become more beneficial for all.  
My parents Håkan and Eva thank you for all the support. You have always let me go my 
own way and encouraged me to seek my dreams. Even tough I had spent a lot of my CSN-
money already you believed and supported me to start over again. I have known that I always 
could get support if I would have needed it. You have both taught me that hard work will get 
you very far in life.     
To my mother Anna-Lena, although you passed away much to early, you are and will always 
be in my heart.   
Anne, it has been so great to have someone to talk to who already have experienced a lot of 
what I have experienced during these years. The energy you posses is incredible. I don’t 
understand how you make things look so easy, nothing seems to be difficult for you, either its 
research, cooking, knitting, singing, running or just being a great doctor. You also have the 
skill to make me look better. Please understand me right, its not because you do something 
poorly. It’s the opposite, all the incredible things you do, somehow rub off on me. I feel so 
blessed to have you and to have shared these years together. I love you!      
  
  45 
6 REFERENCES 
 
1. Hassiotou F, Geddes D. Anatomy of the human mammary gland: Current status of 
knowledge. Clin Anat. 2013 Jan;26(1):29–48.  
2. Macias H, Hinck L. Mammary gland development. Wiley Interdiscip Rev Dev 
Biol. 2012 Jul;1(4):533–57.  
3. Howard BA, Gusterson BA. Human breast development. J Mammary Gland Biol 
Neoplasia. 2000 Apr;5(2):119–37.  
4. Oakes SR, Gallego-Ortega D, Ormandy CJ. The mammary cellular hierarchy and 
breast cancer. Cell Mol Life Sci. 2014 Jul 31;71(22):4301–24.  
5. Ruan W, Kleinberg DL. Insulin-like growth factor I is essential for terminal end 
bud formation and ductal morphogenesis during mammary development. 
Endocrinology. 1999 Nov;140(11):5075–81.  
6. Gallego MI, Binart N, Robinson GW, Okagaki R, Coschigano KT, Perry J, et al. 
Prolactin, growth hormone, and epidermal growth factor activate Stat5 in different 
compartments of mammary tissue and exert different and overlapping 
developmental effects. Dev Biol. 2001 Jan 1;229(1):163–75.  
7. Richards RG, Klotz DM, Walker MP, Diaugustine RP. Mammary gland branching 
morphogenesis is diminished in mice with a deficiency of insulin-like growth 
factor-I (IGF-I), but not in mice with a liver-specific deletion of IGF-I. 
Endocrinology. 2004 Jul;145(7):3106–10.  
8. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, et al. 
Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. 
Lancet. 1998 May 9;351(9113):1393–6.  
9. Samavat H, Kurzer MS. Estrogen metabolism and breast cancer. Cancer Letters. 
2015 Jan 28;356(2 Pt A):231–43.  
10. Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, et al. Estrogen 
receptors: how do they signal and what are their targets. Physiol Rev. 2007 
Jul;87(3):905–31.  
11. Zeps N, Bentel JM, Papadimitriou JM, D'Antuono MF, Dawkins HJ. Estrogen 
receptor-negative epithelial cells in mouse mammary gland development and 
growth. Differentiation. 1998 Mar;62(5):221–6.  
12. Mallepell S, Krust A, Chambon P, Brisken C. Paracrine signaling through the 
epithelial estrogen receptor alpha is required for proliferation and morphogenesis in 
the mammary gland. Proc Natl Acad Sci USA. 2006 Feb 14;103(7):2196–201.  
13. McBryan J, Howlin J, Napoletano S, Martin F. Amphiregulin: role in mammary 
gland development and breast cancer. J Mammary Gland Biol Neoplasia. 2008 
Jun;13(2):159–69.  
14. Ciarloni L, Mallepell S, Brisken C. Amphiregulin is an essential mediator of 
 46 
estrogen receptor alpha function in mammary gland development. Proc Natl Acad 
Sci USA. 2007 Mar 27;104(13):5455–60.  
15. Luetteke NC, Qiu TH, Fenton SE, Troyer KL, Riedel RF, Chang A, et al. Targeted 
inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF 
receptor ligands in mouse mammary gland development. Development. 1999 
Jun;126(12):2739–50.  
16. Chakravorti S, Sheffield L. Acidic and basic fibroblast growth factor mRNA and 
protein in mouse mammary glands. Endocrine. 1996 Apr;4(2):175–82.  
17. Lu P, Ewald AJ, Martin GR, Werb Z. Genetic mosaic analysis reveals FGF 
receptor 2 function in terminal end buds during mammary gland branching 
morphogenesis. Dev Biol. 2008 Sep 1;321(1):77–87.  
18. Silberstein GB, Daniel CW. Reversible inhibition of mammary gland growth by 
transforming growth factor-beta. Science. 1987 Jul 17;237(4812):291–3.  
19. Ewan KB, Shyamala G, Ravani SA, Tang Y, Akhurst R, Wakefield L, et al. Latent 
transforming growth factor-beta activation in mammary gland: regulation by 
ovarian hormones affects ductal and alveolar proliferation. Am J Pathol. 2002 
Jun;160(6):2081–93.  
20. Ingman WV, Robertson SA. Mammary gland development in transforming growth 
factor beta1 null mutant mice: systemic and epithelial effects. Biol Reprod. 2008 
Oct;79(4):711–7.  
21. Fernandez-Valdivia R, Mukherjee A, Creighton CJ, Buser AC, DeMayo FJ, 
Edwards DP, et al. Transcriptional response of the murine mammary gland to acute 
progesterone exposure. Endocrinology. 2008 Dec;149(12):6236–50.  
22. Atwood CS, Hovey RC, Glover JP, Chepko G, Ginsburg E, Robison WG, et al. 
Progesterone induces side-branching of the ductal epithelium in the mammary 
glands of peripubertal mice. J Endocrinol. 2000 Oct;167(1):39–52.  
23. Shyamala G, Chou Y-C, Louie SG, Guzman RC, Smith GH, Nandi S. Cellular 
expression of estrogen and progesterone receptors in mammary glands: regulation 
by hormones, development and aging. J Steroid Biochem Mol Biol. 2002 
Feb;80(2):137–48.  
24. Brisken C, Park S, Vass T, Lydon JP, O'Malley BW, Weinberg RA. A paracrine 
role for the epithelial progesterone receptor in mammary gland development. Proc 
Natl Acad Sci USA. 1998 Apr 28;95(9):5076–81.  
25. Obr AE, Edwards DP. The biology of progesterone receptor in the normal 
mammary gland and in breast cancer. Molecular and Cellular Endocrinology. 2012 
Jun 24;357(1-2):4–17.  
26. Seagroves TN, Lydon JP, Hovey RC, Vonderhaar BK, Rosen JM. C/EBPbeta 
(CCAAT/enhancer binding protein) controls cell fate determination during 
mammary gland development. Molecular Endocrinology. 2000 Mar;14(3):359–68.  
27. Lee HJ, Ormandy CJ. Interplay between progesterone and prolactin in mammary 
development and implications for breast cancer. Molecular and Cellular 
  47 
Endocrinology. 2012 Jun 24;357(1-2):101–7.  
28. Ormandy CJ, Hall RE, Manning DL, Robertson JF, Blamey RW, Kelly PA, et al. 
Coexpression and cross-regulation of the prolactin receptor and sex steroid 
hormone receptors in breast cancer. J Clin Endocrinol Metab. 1997 
Nov;82(11):3692–9.  
29. Berx G, van Roy F. Involvement of members of the cadherin superfamily in 
cancer. Cold Spring Harb Perspect Biol. 2009 Dec;1(6):a003129.  
30. Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for 
combating resistance. Nat Rev Cancer. 2002 Feb;2(2):101–12.  
31. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer 
statistics. CA: A Cancer Journal for Clinicians. 2011 Mar;61(2):69–90.  
32. Hulka BS, Moorman PG. Breast cancer: hormones and other risk factors. 
Maturitas. 2001 Feb 28;38(1):103–13–discussion113–6.  
33. Autier P, Boniol M, La Vecchia C, LaVecchia C, Vatten L, Gavin A, et al. 
Disparities in breast cancer mortality trends between 30 European countries: 
retrospective trend analysis of WHO mortality database. BMJ. 2010;341:c3620.  
34. Kushi LH, Doyle C, McCullough M, Rock CL, Demark-Wahnefried W, Bandera 
EV, et al. American Cancer Society Guidelines on nutrition and physical activity 
for cancer prevention: reducing the risk of cancer with healthy food choices and 
physical activity. CA: A Cancer Journal for Clinicians. 2012. pp. 30–67.  
35. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000 Jan 7;100(1):57–
70.  
36. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 
Mar 4;144(5):646–74.  
37. Krishnamurti U, Silverman JF. HER2 in breast cancer: a review and update. Adv 
Anat Pathol. 2014 Mar;21(2):100–7.  
38. Ebi H, Costa C, Faber AC, Nishtala M, Kotani H, Juric D, et al. PI3K regulates 
MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1. Proceedings of the 
National Academy of Sciences. 2013 Dec 24;110(52):21124–9.  
39. Bergh J. Clinical studies of p53 in treatment and benefit of breast cancer patients. 
Endocr Relat Cancer. 1999 Mar;6(1):51–9.  
40. Chen C-H, Chen R-J. Prevalence of telomerase activity in human cancer. J Formos 
Med Assoc. 2011 May;110(5):275–89.  
41. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971 
Nov 18;285(21):1182–6.  
42. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic 
switch during tumorigenesis. Cell. 1996 Aug 9;86(3):353–64.  
43. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: 
 48 
acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009 Apr;9(4):265–
73.  
44. Foulkes WD, Shuen AY. In brief: BRCA1 and BRCA2. J Pathol. 2013 
Aug;230(4):347–9.  
45. Strauss DC, Thomas JM. Transmission of donor melanoma by organ 
transplantation. Lancet Oncol. 2010 Aug;11(8):790–6.  
46. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg 
effect: the metabolic requirements of cell proliferation. Science. 2009 May 
22;324(5930):1029–33.  
47. Carlson RW, Stockdale FE. The clinical biology of breast cancer. Annu Rev Med. 
1988;39:453–64.  
48. Lopez-Garcia MA, Geyer FC, Lacroix-Triki M, Marchio C, Reis-Filho JS. Breast 
cancer precursors revisited: molecular features and progression pathways. 
Histopathology. 2010 Aug;57(2):171–92.  
49. Simpson PT, Reis-Filho JS, Gale T, Lakhani SR. Molecular evolution of breast 
cancer. J Pathol. 2005 Jan;205(2):248–54.  
50. Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat M-L, et 
al. Generation of a functional mammary gland from a single stem cell. Nature. 
2006 Jan 5;439(7072):84–8.  
51. Daniel CW, De Ome KB, Young JT, Blair PB, Faulkin LJ. The in vivo life span of 
normal and preneoplastic mouse mammary glands: a serial transplantation study. 
Proc Natl Acad Sci USA. 1968 Sep;61(1):53–60.  
52. Luo J, Yin X, Ma T, Lu J. Stem cells in normal mammary gland and breast cancer. 
Am J Med Sci. 2010 Apr;339(4):366–70.  
53. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, et al. 
In vitro propagation and transcriptional profiling of human mammary 
stem/progenitor cells. Genes Dev. 2003 May 15;17(10):1253–70.  
54. Reynolds BA, Weiss S. Clonal and population analyses demonstrate that an EGF-
responsive mammalian embryonic CNS precursor is a stem cell. Dev Biol. 1996 
Apr 10;175(1):1–13.  
55. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces 
apoptosis. The Journal of Cell Biology. 1994 Feb;124(4):619–26.  
56. Paoli P, Giannoni E, Chiarugi P. Anoikis molecular pathways and its role in cancer 
progression. Biochim Biophys Acta. 2013 Dec;1833(12):3481–98.  
57. Dontu G, Al-Hajj M, Abdallah WM, Clarke MF, Wicha MS. Stem cells in normal 
breast development and breast cancer. Cell Prolif. 2003 Oct;36 Suppl 1:59–72.  
58. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A 
cell initiating human acute myeloid leukaemia after transplantation into SCID 
mice. Nature. 1994 Feb 17;367(6464):645–8.  
  49 
59. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that 
originates from a primitive hematopoietic cell. Nat Med. Nature Publishing Group; 
1997;3(7):730–7.  
60. Sonnenschein C, Soto AM, Rangarajan A, Kulkarni P. Competing views on cancer. 
J Biosci. 2014 Apr;39(2):281–302.  
61. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective 
identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. National 
Acad Sciences; 2003;100(7):3983.  
62. Badve S, Nakshatri H. Breast-cancer stem cells-beyond semantics. Lancet Oncol. 
2012 Jan;13(1):e43–8.  
63. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. 
ALDH1 is a marker of normal and malignant human mammary stem cells and a 
predictor of poor clinical outcome. Cell Stem Cell. 2007 Nov;1(5):555–67.  
64. Shah M, Allegrucci C. Keeping an open mind: highlights and controversies of the 
breast cancer stem cell theory. Breast Cancer: Targets and Therapy. 2012;4:155–
66.  
65. Ricardo S, Vieira AF, Gerhard R, Leitao D, Pinto R, Cameselle-Teijeiro JF, et al. 
Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution 
within intrinsic molecular subtype. Journal of Clinical Pathology. 2011 Oct 
22;64(11):937–46.  
66. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, et al. 
Identification of conserved gene expression features between murine mammary 
carcinoma models and human breast tumors. Genome Biol. 2007;8(5):R76.  
67. Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C, et al. 
Stochastic State Transitions Give Rise to Phenotypic Equilibrium in Populations of 
Cancer Cells. Cell. Elsevier Inc; 2011 Aug 19;146(4):633–44.  
68. Owens TW, Naylor MJ. Breast cancer stem cells. Front Physiol. 2013;4:225.  
69. Iqbal J, Chong PY, Tan PH. Breast cancer stem cells: an update. Journal of Clinical 
Pathology. 2013 Jan 15.  
70. Antoniou A, Hébrant A, Dom G, Dumont JE, Maenhaut C. Cancer stem cells, a 
fuzzy evolving concept: a cell population or a cell property? Cell Cycle. 2013 Dec 
15;12(24):3743–8.  
71. Zapperi S, La Porta CAM. Do cancer cells undergo phenotypic switching? The 
case for imperfect cancer stem cell markers. Sci Rep. 2012;2:441.  
72. Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality? Nat 
Med. 2009 Sep;15(9):1010–2.  
73. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse 
embryonic and adult fibroblast cultures by defined factors. Cell. 2006 Aug 
25;126(4):663–76.  
 50 
74. Meyer MJ, Fleming JM, Ali MA, Pesesky MW, Ginsburg E, Vonderhaar BK. 
Dynamic regulation of CD24 and the invasive, CD44posCD24neg phenotype in 
breast cancer cell lines. Breast Cancer Res. 2009;11(6):R82.  
75. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu M-F, et al. Intrinsic 
resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 
2008 May 7;100(9):672–9.  
76. Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/CD44+ breast 
cancer-initiating cells to radiation. J Natl Cancer Inst. 2006 Dec 20;98(24):1777–
85.  
77. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating 
evidence and unresolved questions. Nat Rev Cancer. 2008 Oct;8(10):755–68.  
78. Maenhaut C, Dumont JE, Roger PP, van Staveren WCG. Cancer stem cells: a 
reality, a myth, a fuzzy concept or a misnomer? An analysis. Carcinogenesis. 2010 
Feb;31(2):149–58.  
79. Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast 
cancer. Oncologist. 2004;9(6):606–16.  
80. Weir L, Speers C, D'yachkova Y, Olivotto IA. Prognostic significance of the 
number of axillary lymph nodes removed in patients with node-negative breast 
cancer. J Clin Oncol. 2002 Apr 1;20(7):1793–9.  
81. Bland KI, Scott-Conner CE, Menck H, Winchester DP. Axillary dissection in 
breast-conserving surgery for stage I and II breast cancer: a National Cancer Data 
Base study of patterns of omission and implications for survival. J Am Coll Surg. 
1999 Jun;188(6):586–95–discussion595–6.  
82. Polednak AP. Survival of lymph node-negative breast cancer patients in relation to 
number of lymph nodes examined. Ann Surg. 2003 Feb;237(2):163–7.  
83. Rao R, Euhus D, Mayo HG, Balch C. Axillary node interventions in breast cancer: 
a systematic review. JAMA. 2013 Oct 2;310(13):1385–94.  
84. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and 
sentinel lymphadenectomy for breast cancer. Ann Surg. Lippincott, Williams, and 
Wilkins; 1994;220(3):391.  
85. Fleissig A, Fallowfield LJ, Langridge CI, Johnson L, Newcombe RG, Dixon JM, et 
al. Post-operative arm morbidity and quality of life. Results of the ALMANAC 
randomised trial comparing sentinel node biopsy with standard axillary treatment 
in the management of patients with early breast cancer. Breast Cancer Res Treat. 
2006 Feb;95(3):279–93.  
86. Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, et al. 
Sentinel-lymph-node resection compared with conventional axillary-lymph-node 
dissection in clinically node-negative patients with breast cancer: overall survival 
findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010 
Oct;11(10):927–33.  
87. Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, et al. A 
  51 
randomized comparison of sentinel-node biopsy with routine axillary dissection in 
breast cancer. N Engl J Med. 2003 Aug 7;349(6):546–53.  
88. Pesce C, Morrow M. The need for lymph node dissection in nonmetastatic breast 
cancer. Annu Rev Med. 2013;64:119–29.  
89. Burns KA, Korach KS. Estrogen receptors and human disease: an update. Arch 
Toxicol. 2012 Oct;86(10):1491–504.  
90. Fisher B, Redmond C, Fisher ER, Caplan R. Relative worth of estrogen or 
progesterone receptor and pathologic characteristics of differentiation as indicators 
of prognosis in node negative breast cancer patients: findings from National 
Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol. 1988 
Jul;6(7):1076–87.  
91. Bentzon N, Düring M, Rasmussen BB, Mouridsen H, KROMAN N. Prognostic 
effect of estrogen receptor status across age in primary breast cancer. Int J Cancer. 
2008 Mar 1;122(5):1089–94.  
92. Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. 
American Society of Clinical Oncology/College of American Pathologists 
Guideline Recommendations for Immunohistochemical Testing of Estrogen and 
Progesterone Receptors in Breast Cancer. Journal of Clinical Oncology. 2010 May 
27;28(16):2784–95.  
93. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by 
immunohistochemistry is superior to the ligand-binding assay for predicting 
response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999 
May;17(5):1474–81.  
94. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin 
J, Gray R, Clarke M, Cutter D, et al. Relevance of breast cancer hormone receptors 
and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis 
of randomised trials. Lancet. 2011 Aug 27;378(9793):771–84.  
95. Horwitz KB, McGuire WL. Estrogen control of progesterone receptor in human 
breast cancer. Correlation with nuclear processing of estrogen receptor. J Biol 
Chem. 1978 Apr 10;253(7):2223–8.  
96. Savouret JF, Bailly A, Misrahi M, Rauch C, Redeuilh G, Chauchereau A, et al. 
Characterization of the hormone responsive element involved in the regulation of 
the progesterone receptor gene. EMBO J. 1991 Jul;10(7):1875–83.  
97. Purdie CA, Quinlan P, Jordan LB, Ashfield A, Ogston S, Dewar JA, et al. 
Progesterone receptor expression is anindependent prognostic variable in 
earlybreast cancer: a population-based study. Nature Publishing Group; 2013 Dec 
3;110(3):565–72.  
98. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American 
Society of Clinical Oncology 2007 Update of Recommendations for the Use of 
Tumor Markers in Breast Cancer. Journal of Clinical Oncology. 2007 Nov 
16;25(33):5287–312.  
99. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast 
 52 
cancer: prognostic and predictive potential. Lancet Oncol. 2010 Feb;11(2):174–83.  
100. Pathmanathan N, Balleine RL. Ki67 and proliferation in breast cancer. Journal of 
Clinical Pathology. 2013 May 22;66(6):512–6.  
101. de Azambuja E, Cardoso F, de Castro G, Colozza M, Mano MS, Durbecq V, et al. 
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published 
studies involving 12,155 patients. Br J Cancer. 2007 May 21;96(10):1504–13.  
102. Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, et al. 
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 
in Breast Cancer working group. Journal of the National Cancer Institute. 2011. pp. 
1656–64.  
103. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, et al. 
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast 
cancer. N Engl J Med. 2005 Oct 20;353(16):1673–84.  
104. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. 
Treatment of HER2-positive breast cancer: current status and future perspectives. 
Nature Reviews Clinical Oncology. 2012 Jan;9(1):16–32.  
105. Winstanley J, Cooke T, Murray GD, Platt-Higgins A, George WD, Holt S, et al. 
The long term prognostic significance of c-erbB-2 in primary breast cancer. Br J 
Cancer. 1991 Mar;63(3):447–50.  
106. Paterson MC, Dietrich KD, Danyluk J, Paterson AH, Lees AW, Jamil N, et al. 
Correlation between c-erbB-2 amplification and risk of recurrent disease in node-
negative breast cancer. Cancer Res. 1991 Jan 15;51(2):556–67.  
107. Yin W, Jiang Y, Shen Z, Shao Z, Lu J. Trastuzumab in the adjuvant treatment of 
HER2-positive early breast cancer patients: a meta-analysis of published 
randomized controlled trials. PLoS ONE. 2011;6(6):e21030.  
108. Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W. Human breast 
cancer: correlation of relapse and survival with amplification of the HER-2/neu 
oncogene. Science. 1987 Jan 9;235(4785):177–82.  
109. Rakha EA, Reis-Filho JS, Baehner F, Dabbs DJ, Decker T, Eusebi V, et al. Breast 
cancer prognostic classification in the molecular era: the role of histological grade. 
Breast Cancer Res. 2010;12(4):207.  
110. Sobin LH, Gospodarowicz MK, Wittekind C (editors). Classification of Malignant 
Tumours, 7th edition. John Wiley & Sons; 2009.   
111. Kiely BE, Soon YY, Tattersall MHN, Stockler MR. How Long Have I Got? 
Estimating Typical, Best-Case, and Worst-Case Scenarios for Patients Starting 
First-Line Chemotherapy for Metastatic Breast Cancer: A Systematic Review of 
Recent Randomized Trials. Journal of Clinical Oncology. 2011 Jan 28;29(4):456–
63.  
112. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and 
survival in 24,740 breast cancer cases. Cancer. 1989 Jan 1;63(1):181–7.  
  53 
113. Koscielny S, Tubiana M, Lê MG, Valleron AJ, Mouriesse H, Contesso G, et al. 
Breast cancer: relationship between the size of the primary tumour and the 
probability of metastatic dissemination. Br J Cancer. 1984 Jun;49(6):709–15.  
114. Benson JR, Jatoi I, Keisch M, Esteva FJ, Makris A, Jordan VC. Early breast 
cancer. The Lancet. Elsevier Ltd; 2009 Apr 25;373(9673):1463–79.  
115. Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in 
primary breast cancer. Breast Cancer Res Treat. 1992;22(3):207–19.  
116. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value 
of histological grade in breast cancer: experience from a large study with long-term 
follow-up. Histopathology. 1991 Nov;19(5):403–10.  
117. Frkovic-Grazio S, Bracko M. Long term prognostic value of Nottingham 
histological grade and its components in early (pT1N0M0) breast carcinoma. 
Journal of Clinical Pathology. 2002 Feb;55(2):88–92.  
118. Howlader N, Chen VW, Ries LAG, Loch MM, Lee R, DeSantis C, et al. Overview 
of breast cancer collaborative stage data items-their definitions, quality, usage, and 
clinical implications: A review of SEER data for 2004-2010. Cancer. 2014 Nov 
20;120:3771–80.  
119. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, et al. Gene Expression 
Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade 
To Improve Prognosis. J Natl Cancer Inst. 2006 Feb 14;98(4):262–72.  
120. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. 
Molecular portraits of human breast tumours. Nature. 2000 Aug 
17;406(6797):747–52.  
121. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene 
expression patterns of breast carcinomas distinguish tumor subclasses with clinical 
implications. Proc Natl Acad Sci USA. 2001 Sep 11;98(19):10869–74.  
122. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. 
Molecular Oncology. 2011 Feb;5(1):5–23.  
123. Norum JH, Andersen K, Sørlie T. Lessons learned from the intrinsic subtypes of 
breast cancer in the quest for precision therapy. Br J Surg. 2014 Jul;101(8):925–38.  
124. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated 
observation of breast tumor subtypes in independent gene expression data sets. 
Proc Natl Acad Sci USA. 2003 Jul 8;100(14):8418–23.  
125. Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, et al. 
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes. Journal of 
Clinical Oncology. 2009 Mar 6;27(8):1160–7.  
126. Lim E, Vaillant F, Di Wu, Forrest NC, Pal B, Hart AH, et al. Aberrant luminal 
progenitors as the candidate target population for basal tumor development in. 
Nature Publishing Group. Nature Publishing Group; 2009 Aug 2;:1–9.  
127. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, et al. 
 54 
Residual breast cancers after conventional therapy display mesenchymal as well as 
tumor-initiating features. Proceedings of the National Academy of Sciences. 2009 
Aug 18;106(33):13820–5.  
128. Xiao X, Wang P, Chou K-C. Recent progresses in identifying nuclear receptors and 
their families. Curr Top Med Chem. 2013;13(10):1192–200.  
129. Helsen C, Claessens F. Looking at nuclear receptors from a new angle. Molecular 
and Cellular Endocrinology. 2014 Jan 25;382(1):97–106.  
130. Acevedo ML, Kraus WL. Transcriptional activation by nuclear receptors. Essays 
Biochem. 2004;40:73–88.  
131. Jensen EV. Steroid hormones, receptors, and antagonists. Ann N Y Acad Sci. 1996 
Apr 30;784:1–17.  
132. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a 
novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA. 1996 
Jun 11;93(12):5925–30.  
133. Li S, Han B, Liu G, Li S, Ouellet J, Labrie F, et al. Immunocytochemical 
localization of sex steroid hormone receptors in normal human mammary gland. J 
Histochem Cytochem. 2010 Jun;58(6):509–15.  
134. Thomas C, Gustafsson J-Å. The different roles of ER subtypes in cancer biology 
and therapy. Nat Rev Cancer. 2011 Aug;11(8):597–608.  
135. Enmark E, Pelto-Huikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried G, et 
al. Human estrogen receptor beta-gene structure, chromosomal localization, and 
expression pattern. J Clin Endocrinol Metab. 1997 Dec;82(12):4258–65.  
136. Moore JT, McKee DD, Slentz-Kesler K, Moore LB, Jones SA, Horne EL, et al. 
Cloning and characterization of human estrogen receptor β isoforms. Biochemical 
and Biophysical Research Communications. Elsevier; 1998;247(1):75–8.  
137. Ogawa S, Inoue S, Watanabe T, Orimo A, Hosoi T, Ouchi Y, et al. Molecular 
cloning and characterization of human estrogen receptor betacx: a potential 
inhibitor ofestrogen action in human. Nucleic Acids Res. 1998 Aug 1;26(15):3505–
12.  
138. Leung Y-K, Mak P, Hassan S, Ho S-M. Estrogen receptor (ER)-beta isoforms: a 
key to understanding ER-beta signaling. Proc Natl Acad Sci USA. 2006 Aug 
29;103(35):13162–7.  
139. Hartman J, Ström A, Gustafsson J-Å. Estrogen receptor beta in breast cancer--
diagnostic and therapeutic implications. Steroids. 2009 Aug;74(8):635–41.  
140. Kumar V, Green S, Stack G, Berry M, Jin JR, Chambon P. Functional domains of 
the human estrogen receptor. Cell. 1987 Dec 24;51(6):941–51.  
141. Tora L, White J, Brou C, Tasset D, Webster N, Scheer E, et al. The human estrogen 
receptor has two independent nonacidic transcriptional activation functions. Cell. 
1989 Nov 3;59(3):477–87.  
  55 
142. Klein-Hitpass L, Ryffel GU, Heitlinger E, Cato AC. A 13 bp palindrome is a 
functional estrogen responsive element and interacts specifically with estrogen 
receptor. Nucleic Acids Res. 1988 Jan 25;16(2):647–63.  
143. Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L, Horwitz KB. The partial 
agonist activity of antagonist-occupied steroid receptors is controlled by a novel 
hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. 
Molecular Endocrinology. 1997 Jun;11(6):693–705.  
144. Mueller-Fahrnow A, Egner U. Ligand-binding domain of estrogen receptors. Curr 
Opin Biotechnol. 1999 Dec;10(6):550–6.  
145. Norris JD, Fan D, Kerner SA, McDonnell DP. Identification of a third autonomous 
activation domain within the human estrogen receptor. Molecular Endocrinology. 
1997 Jun;11(6):747–54.  
146. Sommer S, Fuqua SA. Estrogen receptor and breast cancer. Semin Cancer Biol. 
2001 Oct;11(5):339–52.  
147. Ryan KJ. Biochemistry of aromatase: significance to female reproductive 
physiology. Cancer Res. 1982 Aug;42(8 Suppl):3342s–3344s.  
148. Dösch J, Dörr HG, Wildt L. Exposure to endogenous estrogens during lifetime. 
Springer; 2001;:81–99.  
149. Skliris GP, Nugent ZJ, Rowan BG, Penner CR, Watson PH, Murphy LC. A 
phosphorylation code for oestrogen receptor-alpha predicts clinical outcome to 
endocrine therapy in breast cancer. Endocr Relat Cancer. 2010 Sep;17(3):589–97.  
150. Hamilton-Burke W, Coleman L, Cummings M, Green CA, Holliday DL, Horgan 
K, et al. Phosphorylation of estrogen receptor beta at serine 105 is associated with 
good prognosis in breast cancer. Am J Pathol. 2010 Sep;177(3):1079–86.  
151. Chakraborty S, Willett H, Biswas PK. Insight into estrogen receptor beta-beta and 
alpha-beta homo- and heterodimerization: A combined molecular dynamics and 
sequence analysis study. Biophys Chem. 2012 Aug;170:42–50.  
152. Pike AC, Brzozowski AM, Hubbard RE, Bonn T, Thorsell AG, Engström O, et al. 
Structure of the ligand-binding domain of oestrogen receptor beta in the presence 
of a partial agonist and a full antagonist. EMBO J. 1999 Sep 1;18(17):4608–18.  
153. Smith CL, Nawaz Z, O'Malley BW. Coactivator and corepressor regulation of the 
agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. 
Molecular Endocrinology. 1997 Jun;11(6):657–66.  
154. Lavinsky RM, Jepsen K, Heinzel T, Torchia J, Mullen TM, Schiff R, et al. Diverse 
signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT 
complexes. Proc Natl Acad Sci USA. 1998 Mar 17;95(6):2920–5.  
155. Murphy LC, Watson P. Steroid receptors in human breast tumorigenesis and breast 
cancer progression. Biomed Pharmacother. 2002 Mar;56(2):65–77.  
156. Anbalagan M, Rowan BG. Estrogen receptor alpha phosphorylation and its 
functional impact in human breast cancer. Molecular and Cellular Endocrinology. 
 56 
2015 Jan 15.  
157. Beatson G. On the Treatment of Inoperable Cases of Carcinoma of the Mamma: 
Suggestions for a new Method of Treatment, with Illustrative Cases. The Lancet. 
1896 Jul;148(3803):162–5.  
158. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med. 
2006 Jan 19;354(3):270–82.  
159. Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, 
menopause, and breast cancer risk: individual participant meta-analysis, including 
118 964 women with breast cancer from 117 epidemiological studies. Lancet 
Oncol. 2012 Nov;13(11):1141–51.  
160. Yue W, Yager JD, Wang J-P, Jupe ER, Santen RJ. Estrogen receptor-dependent 
and independent mechanisms of breast cancer carcinogenesis. Steroids. 2013 
Feb;78(2):161–70.  
161. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick 
ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal 
women: principal results From the Women's Health Initiative randomized 
controlled trial. JAMA. 2002 Jul 17;288(3):321–33.  
162. Beral V, Million Women Study Collaborators. Breast cancer and hormone-
replacement therapy in the Million Women Study. Lancet. 2003 Aug 
9;362(9382):419–27.  
163. Mikkola TS, Tuomikoski P, Lyytinen H, Korhonen P, Hoti F, Vattulainen P, et al. 
Estradiol-based postmenopausal hormone therapy and risk of cardiovascular and 
all-cause mortality. Menopause. 2015 Mar 23.  
164. Santen RJ, Allred DC, Ardoin SP, Archer DF, Boyd N, Braunstein GD, et al. 
Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin 
Endocrinol Metab. 2010 Jul;95(7 Suppl 1):s1–s66.  
165. Magnusson C, Baron J, Persson I, Wolk A, Bergström R, Trichopoulos D, et al. 
Body size in different periods of life and breast cancer risk in post-menopausal 
women. Int J Cancer. 1998 Mar 30;76(1):29–34.  
166. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of 
chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-
year survival: an overview of the randomised trials. Lancet. 2005 
May;365(9472):1687–717.  
167. Haldosén L-A, Zhao C, Dahlman-Wright K. Estrogen receptor beta in breast 
cancer. Molecular and Cellular Endocrinology. 2014 Jan 25;382(1):665–72.  
168. Rizza P, Barone I, Zito D, Giordano F, Lanzino M, De Amicis F, et al. Estrogen 
receptor beta as a novel target of androgen receptor action in breast cancer cell 
lines. Breast Cancer Res. 2014;16(1):R21.  
169. Lattrich C, Schüler S, Häring J, Skrzypczak M, Ortmann O, Treeck O. Effects of a 
combined treatment with tamoxifen and estrogen receptor β agonists on human 
breast cancer cell lines. Arch Gynecol Obstet. 2014 Jan;289(1):163–71.  
  57 
170. Ström A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson J-Å. Estrogen 
receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer 
cell line T47D. Proc Natl Acad Sci USA. 2004 Feb 10;101(6):1566–71.  
171. Horimoto Y, Hartman J, Millour J, Pollock S, Olmos Y, Ho K-K, et al. ERβ1 
represses FOXM1 expression through targeting ERα to control cell proliferation in 
breast cancer. Am J Pathol. 2011 Sep;179(3):1148–56.  
172. Helguero LA, Faulds MH, Gustafsson J-Å, Haldosén L-A. Estrogen receptors alfa 
(ERalpha) and beta (ERbeta) differentially regulate proliferation and apoptosis of 
the normal murine mammary epithelial cell line HC11. Oncogene. 2005 Oct 
6;24(44):6605–16.  
173. Hartman J, Lindberg K, Morani A, Inzunza J, Ström A, Gustafsson J-Å. Estrogen 
receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts. 
Cancer Res. 2006 Dec 1;66(23):11207–13.  
174. Thomas C, Rajapaksa G, Nikolos F, Hao R, Katchy A, McCollum CW, et al. 
ERbeta1 represses basal breast cancer epithelial to mesenchymal transition by 
destabilizing EGFR. Breast Cancer Res. 2012;14(6):R148.  
175. Skliris GP, Leygue E, Watson PH, Murphy LC. Estrogen receptor alpha negative 
breast cancer patients: estrogen receptor beta as a therapeutic target. J Steroid 
Biochem Mol Biol. 2008 Mar;109(1-2):1–10.  
176. Roger P, Sahla ME, Mäkelä S, Gustafsson JA, Baldet P, Rochefort H. Decreased 
expression of estrogen receptor beta protein in proliferative preinvasive mammary 
tumors. Cancer Res. 2001 Mar 15;61(6):2537–41.  
177. Skliris GP, Munot K, Bell SM, Carder PJ, Lane S, Horgan K, et al. Reduced 
expression of oestrogen receptor beta in invasive breast cancer and its re-
expression using DNA methyl transferase inhibitors in a cell line model. J Pathol. 
2003 Oct;201(2):213–20.  
178. Sugiura H, Toyama T, Hara Y, Zhang Z, Kobayashi S, Fujii Y, et al. Expression of 
estrogen receptor beta wild-type and its variant ERbetacx/beta2 is correlated with 
better prognosis in breast cancer. Jpn J Clin Oncol. 2007 Nov;37(11):820–8.  
179. Nakopoulou L, Lazaris AC, Panayotopoulou EG, Giannopoulou I, Givalos N, 
Markaki S, et al. The favourable prognostic value of oestrogen receptor beta 
immunohistochemical expression in breast cancer. Journal of Clinical Pathology. 
2004 May;57(5):523–8.  
180. Zhang H, Zhang Z, Xuan L, Zheng S, Guo L, Zhan Q, et al. Evaluation of ER-α, 
ER-Β1 and ER-Β2 expression and correlation with clinicopathologic factors in 
invasive luminal subtype breast cancers. Clin Transl Oncol. 2012 Mar;14(3):225–
31.  
181. Honma N, Horii R, Iwase T, Saji S, Younes M, Takubo K, et al. Clinical 
Importance of Estrogen Receptor-  Evaluation in Breast Cancer Patients Treated 
With Adjuvant Tamoxifen Therapy. Journal of Clinical Oncology. 2008 Aug 
1;26(22):3727–34.  
182. Myers E, Fleming FJ, Crotty TB, Kelly G, McDermott EW, O'Higgins NJ, et al. 
 58 
Inverse relationship between ER-beta and SRC-1 predicts outcome in endocrine-
resistant breast cancer. Br J Cancer. 2004 Nov 1;91(9):1687–93.  
183. Marotti JD, Collins LC, Hu R, Tamimi RM. Estrogen receptor. Modern Pathology. 
Nature Publishing Group; 2009 Nov 6;23(2):197–204.  
184. Borgquist S, Holm C, Stendahl M, Anagnostaki L, Landberg G, Jirström K. 
Oestrogen receptors alpha and beta show different associations to 
clinicopathological parameters and their co-expression might predict a better 
response to endocrine treatment in breast cancer. Journal of Clinical Pathology. 
2008 Feb;61(2):197–203.  
185. Novelli F, Milella M, Melucci E, Di Benedetto A. A divergent role for estrogen 
receptor-beta in node-positive and node-negative breast cancer classified according 
to molecular subtypes: an observational …. Breast Cancer …. 2008.  
186. Skliris GP, Parkes AT, Limer JL, Burdall SE, Carder PJ, Speirs V. Evaluation of 
seven oestrogen receptor beta antibodies for immunohistochemistry, western 
blotting, and flow cytometry in human breast tissue. J Pathol. 2002 
Jun;197(2):155–62.  
187. Shaaban AM, Green AR, Karthik S, Alizadeh Y, Hughes TA, Harkins L, et al. 
Nuclear and Cytoplasmic Expression of ER 1, ER 2, and ER 5 Identifies Distinct 
Prognostic Outcome for Breast Cancer Patients. Clinical Cancer Research. 2008 
Aug 15;14(16):5228–35.  
188. Taipale M, Kaminen N, Nopola-Hemmi J, Haltia T, Myllyluoma B, Lyytinen H, et 
al. A candidate gene for developmental dyslexia encodes a nuclear tetratricopeptide 
repeat domain protein dynamically regulated in brain. Proc Natl Acad Sci USA. 
2003 Sep 30;100(20):11553–8.  
189. Kere J. The molecular genetics and neurobiology of developmental dyslexia as 
model of a complex phenotype. Biochemical and Biophysical Research 
Communications. 2014 Sep 19;452(2):236–43.  
190. Massinen S, Tammimies K, Tapia-Páez I, Matsson H, Hokkanen M-E, Söderberg 
O, et al. Functional interaction of DYX1C1 with estrogen receptors suggests 
involvement of hormonal pathways in dyslexia. Hum Mol Genet. 2009 Aug 
1;18(15):2802–12.  
191. Tammimies K, Tapia-Paez I, Ruegg J, Rosin G, Kere J, Gustafsson JA, et al. The 
rs3743205 SNP Is Important for the Regulation of the Dyslexia Candidate Gene 
DYX1C1 by Estrogen Receptor   and DNA Methylation. Molecular 
Endocrinology. 2012 Mar 29;26(4):619–29.  
192. Threlkeld SW, McClure MM, Bai J, Wang Y, LoTurco JJ, Rosen GD, et al. 
Developmental disruptions and behavioral impairments in rats following in utero 
RNAi of Dyx1c1. Brain Res Bull. 2007 Mar 15;71(5):508–14.  
193. Chandrasekar G, Vesterlund L, Hultenby K, Tapia-Páez I, Kere J. The zebrafish 
orthologue of the dyslexia candidate gene DYX1C1 is essential for cilia growth 
and function. PLoS ONE. 2013;8(5):e63123.  
194. Tarkar A, Loges NT, Slagle CE, Francis R, Dougherty GW, Tamayo JV, et al. 
  59 
DYX1C1 is required for axonemal dynein assembly and ciliary motility. Nature 
Genetics. 2013 Sep;45(9):995–1003.  
195. Chen Y, Zhao M, Wang S, Chen J, Wang Y, Cao Q, et al. A novel role for 
DYX1C1, a chaperone protein for both Hsp70 and Hsp90, in breast cancer. J 
Cancer Res Clin Oncol. 2009 Sep;135(9):1265–76.  
196. Kim Y-J, Huh J-W, Kim D-S, Bae M-I, Lee J-R, Ha H-S, et al. Molecular 
characterization of the DYX1C1 gene and its application as a cancer biomarker. J 
Cancer Res Clin Oncol. 2009 Feb;135(2):265–70.  
197. Longoni N, Kunderfranco P, Pellini S, Albino D, Mello-Grand M, Pinton S, et al. 
Aberrant expression of the neuronal-specific protein DCDC2 promotes malignant 
phenotypes and is associated with prostate cancer progression. Oncogene. 2013 
May 2;32(18):2315–24–2324.e1–4.  
198. Schmid BC, Rezniczek GA, Fabjani G, Yoneda T, Leodolter S, Zeillinger R. The 
neuronal guidance cue Slit2 induces targeted migration and may play a role in brain 
metastasis of breast cancer cells. Breast Cancer Res Treat. 2007 Dec;106(3):333–
42.  
199. Legg JA, Herbert JMJ, Clissold P, Bicknell R. Slits and Roundabouts in cancer, 
tumour angiogenesis and endothelial cell migration. Angiogenesis. 2008;11(1):13–
21.  
200. Tryggvadóttir L, Gislum M, Bray F, Klint Å, Hakulinen T, Storm HH, et al. Trends 
in the survival of patients diagnosed with breast cancer in the Nordic countries 
1964-2003 followed up to the end of 2006. Acta Oncol. 2010 Jun;49(5):624–31.  
201. Kalager M, Zelen M, Langmark F, Adami H-O. Effect of screening mammography 
on breast-cancer mortality in Norway. N Engl J Med. 2010 Sep 23;363(13):1203–
10.  
202. Bergh J, Frisell J, Rydén L, Malmström P, Ahlgren J, Azavedo E, et al. Nationellt 
Vårdprogram Bröstcancer (National Guidelines for Breast Cancer Treatment) 
[Internet]. SweBCG; 2014. Available from: http://www.cancercentrum.se, accessed 
on 24/04/2015.  
203. Engholm G, Ferlay J, Christensen N, Kejs AMT, Johannesen TB, Khan S, Milter 
MC, Ólafsdóttir E, Petersen T, Pukkala E, Stenz F, Storm HH. NORDCAN: 
Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, 
Version 7.0 (17.12.2014). Association of the Nordic Cancer Registries. Danish 
Cancer Society. Available from http://www.ancr.nu, accessed on 24/04/2015.  
204. Litière S, Werutsky G, Fentiman IS, Rutgers E, Christiaens M-R, Van Limbergen 
E, et al. Breast conserving therapy versus mastectomy for stage I-II breast cancer: 
20 year follow-up of the EORTC 10801 phase 3 randomised trial. Lancet Oncol. 
2012 Apr;13(4):412–9.  
205. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. 
Twenty-year follow-up of a randomized trial comparing total mastectomy, 
lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast 
cancer. N Engl J Med. 2002 Oct 17;347(16):1233–41.  
 60 
206. Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, et al. 
Randomized multicenter trial of sentinel node biopsy versus standard axillary 
treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006 
May 3;98(9):599–609.  
207. Celebioglu F, Sylvan M, Perbeck L, Bergkvist L, Frisell J. Intraoperative sentinel 
lymph node examination by frozen section, immunohistochemistry and imprint 
cytology during breast surgery--a prospective study. Eur J Cancer. 2006 
Mar;42(5):617–20.  
208. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, et al. Effects of 
radiotherapy and of differences in the extent of surgery for early breast cancer on 
local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 
2005 Dec 17;366(9503):2087–106.  
209. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Darby S, McGale 
P, Correa C, Taylor C, Arriagada R, et al. Effect of radiotherapy after breast-
conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-
analysis of individual patient data for 10,801 women in 17 randomised trials. 
Lancet. 2011 Nov 12;378(9804):1707–16.  
210. Kurtz J, EUSOMA Working Party. The curative role of radiotherapy in the 
treatment of operable breast cancer. European journal of cancer (Oxford, England : 
1990). 2002. pp. 1961–74.  
211. Lind PA, Wennberg B, Gagliardi G, Fornander T. Pulmonary complications 
following different radiotherapy techniques for breast cancer, and the association to 
irradiated lung volume and dose. Breast Cancer Res Treat. 2001 Aug;68(3):199–
210.  
212. Swedborg I, Wallgren A. The effect of pre- and postmastectomy radiotherapy on 
the degree of edema, shoulder-joint mobility, and gripping force. Cancer. 1981 Mar 
1;47(5):877–81.  
213. James ML, Lehman M, Hider PN, Jeffery M, Hickey BE, Francis DP. Fraction size 
in radiation treatment for breast conservation in early breast cancer. Cochrane 
Database Syst Rev. 2010;(11):CD003860.  
214. Coezy E, Borgna JL, Rochefort H. Tamoxifen and metabolites in MCF7 cells: 
correlation between binding to estrogen receptor and inhibition of cell growth. 
Cancer Res. 1982 Jan;42(1):317–23.  
215. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast 
cancer. Cochrane Database Syst Rev. 2001;(1):CD000486.  
216. Evans CT, Ledesma DB, Schulz TZ, Simpson ER, Mendelson CR. Isolation and 
characterization of a complementary DNA specific for human aromatase-system 
cytochrome P-450 mRNA. Proc Natl Acad Sci USA. 1986 Sep;83(17):6387–91.  
217. Geisler J, King N, Anker G, Ornati G, Di Salle E, Lønning PE, et al. In vivo 
inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, 
in postmenopausal breast cancer patients. Clin Cancer Res. 1998 Sep;4(9):2089–
93.  
  61 
218. Thijssen JH, Blankenstein MA. Endogenous oestrogens and androgens in normal 
and malignant endometrial and mammary tissues. Eur J Cancer Clin Oncol. 1989 
Dec;25(12):1953–9.  
219. Josefsson ML, Leinster SJ. Aromatase inhibitors versus tamoxifen as adjuvant 
hormonal therapy for oestrogen sensitive early breast cancer in post-menopausal 
women: meta-analyses of monotherapy, sequenced therapy and extended therapy. 
Breast. 2010 Apr;19(2):76–83.  
220. Dowsett M, Haynes BP. Hormonal effects of aromatase inhibitors: focus on 
premenopausal effects and interaction with tamoxifen. J Steroid Biochem Mol 
Biol. 2003 Sep;86(3-5):255–63.  
221. Gaillard S, Stearns V. Aromatase inhibitor-associated bone and musculoskeletal 
effects: new evidence defining etiology and strategies for management. Breast 
Cancer Res. 2011;13(2):205.  
222. Weigel RJ, deConinck EC. Transcriptional control of estrogen receptor in estrogen 
receptor-negative breast carcinoma. Cancer Res. 1993 Aug 1;53(15):3472–4.  
223. Kuukasjärvi T, Kononen J, Helin H, Holli K, Isola J. Loss of estrogen receptor in 
recurrent breast cancer is associated with poor response to endocrine therapy. J 
Clin Oncol. American Society of Clinical Oncology; 1996;14(9):2584–9.  
224. Naughton C, MacLeod K, Kuske B, Clarke R, Cameron DA, Langdon SP. 
Progressive loss of estrogen receptor alpha cofactor recruitment in endocrine 
resistance. Molecular Endocrinology. 2007 Nov;21(11):2615–26.  
225. Shi L, Dong B, Li Z, Lu Y, Ouyang T, Li J, et al. Expression of ER-α36, a novel 
variant of estrogen receptor α, and resistance to tamoxifen treatment in breast 
cancer. Journal of Clinical Oncology. 2009 Jul 20;27(21):3423–9.  
226. Zhang QX, Borg A, Wolf DM, Oesterreich S, Fuqua SA. An estrogen receptor 
mutant with strong hormone-independent activity from a metastatic breast cancer. 
Cancer Res. 1997 Apr 1;57(7):1244–9.  
227. Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh I-T, et al. 
Prognostic and predictive value of the 21-gene recurrence score assay in 
postmenopausal women with node-positive, oestrogen-receptor-positive breast 
cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet 
Oncol. 2010 Jan;11(1):55–65.  
228. Wigertz A, Ahlgren J, Holmqvist M, Fornander T, Adolfsson J, Lindman H, et al. 
Adherence and discontinuation of adjuvant hormonal therapy in breast cancer 
patients: a population-based study. Breast Cancer Res Treat. 2012 
May;133(1):367–73.  
229. van de Water W, Bastiaannet E, Hille ETM, Meershoek-Klein Kranenbarg EM, 
Putter H, Seynaeve CM, et al. Age-specific nonpersistence of endocrine therapy in 
postmenopausal patients diagnosed with hormone receptor-positive breast cancer: a 
TEAM study analysis. Oncologist. 2012;17(1):55–63.  
230. Love RR, Leventhal H, Easterling DV, Nerenz DR. Side effects and emotional 
distress during cancer chemotherapy. Cancer. 1989 Feb 1;63(3):604–12.  
 62 
231. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of adjuvant 
tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An 
overview of 61 randomized trials among 28,896 women. N Engl J Med. 1988 Dec 
29;319(26):1681–92.  
232. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Peto R, Davies C, 
Godwin J, Gray R, Pan HC, et al. Comparisons between different 
polychemotherapy regimens for early breast cancer: meta-analyses of long-term 
outcome among 100,000 women in 123 randomised trials. Lancet. 2012 Feb 
4;379(9814):432–44.  
233. Chabner BA, Roberts TG. Timeline: Chemotherapy and the war on cancer. Nat 
Rev Cancer. 2005 Jan;5(1):65–72.  
234. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of 
preoperative chemotherapy on the outcome of women with operable breast cancer. 
J Clin Oncol. 1998 Aug;16(8):2672–85.  
235. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, 
Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results 
from the European Organization for Research and Treatment of Cancer trial 10902. 
J Clin Oncol. 2001 Nov 15;19(22):4224–37.  
236. Mauri D, Pavlidis N, Ioannidis JPA. Neoadjuvant versus adjuvant systemic 
treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005 Feb 
2;97(3):188–94.  
237. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, et al. 
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 
monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast 
cancer. J Clin Oncol. 1996 Mar;14(3):737–44.  
238. Baselga J, Albanell J, Molina MA, Arribas J. Mechanism of action of trastuzumab 
and scientific update. Semin Oncol. 2001 Oct;28(5 Suppl 16):4–11.  
239. Nahta R, Esteva FJ. Herceptin: mechanisms of action and resistance. Cancer 
Letters. 2006 Feb 8;232(2):123–38.  
240. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use 
of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast 
cancer that overexpresses HER2. N Engl J Med. 2001 Mar 15;344(11):783–92.  
241. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, 
et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N 
Engl J Med. 2005 Oct 20;353(16):1659–72.  
242. Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, et al. 
Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst 
Rev. 2012;4:CD006243.  
243. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, et al. Targeting 
ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer 
Cell. 2002 Aug;2(2):127–37.  
  63 
244. Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, et al. 
A unique structure for epidermal growth factor receptor bound to GW572016 
(Lapatinib): relationships among protein conformation, inhibitor off-rate, and 
receptor activity in tumor cells. Cancer Res. 2004 Sep 15;64(18):6652–9.  
245. Gridelli C, Maione P, Rossi A, De Marinis F. The role of bevacizumab in the 
treatment of non-small cell lung cancer: current indications and future 
developments. Oncologist. 2007 Oct;12(10):1183–93.  
246. Macedo LT, da Costa Lima AB, Sasse AD. Addition of bevacizumab to first-line 
chemotherapy in advanced colorectal cancer: a systematic review and meta-
analysis, with emphasis on chemotherapy subgroups. BMC Cancer. 2012;12:89.  
247. Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, et al. Adjuvant 
bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): 
primary results of a randomised, phase 3 trial. Lancet Oncol. 2013 Sep;14(10):933–
42.  
248. Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, et al. 
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. 
N Engl J Med. 2012 Feb 9;366(6):520–9.  
249. deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva 
JM, et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer 
cells with aberrant Akt Activity. Clin Cancer Res. 2004 Dec 1;10(23):8059–67.  
250. Boulay A, Rudloff J, Ye J, Zumstein-Mecker S, O'Reilly T, Evans DB, et al. Dual 
inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in 
models of breast cancer. Clin Cancer Res. 2005 Jul 15;11(14):5319–28.  
251. van der Groep P, Bouter A, van der Zanden R, Siccama I, Menko FH, Gille JJP, et 
al. Distinction between hereditary and sporadic breast cancer on the basis of 
clinicopathological data. Journal of Clinical Pathology. 2006 Jun;59(6):611–7.  
252. Mavaddat N, Antoniou AC, Easton DF, Garcia-Closas M. Genetic susceptibility to 
breast cancer. Molecular Oncology. 2010 Jun;4(3):174–91.  
253. Antoniou AC, Easton DF. Models of genetic susceptibility to breast cancer. 
Oncogene. 2006 Sep 25;25(43):5898–905.  
254. Campeau PM, Foulkes WD, Tischkowitz MD. Hereditary breast cancer: new 
genetic developments, new therapeutic avenues. Hum Genet. 2008 Aug;124(1):31–
42.  
255. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. Journal 
of Clinical Oncology. 2007 Apr 10;25(11):1329–33.  
256. Lostumbo L, Carbine NE, Wallace J. Prophylactic mastectomy for the prevention 
of breast cancer. Cochrane Database Syst Rev. 2010;(11):CD002748.  
257. Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, et al. PALB2, 
which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. 
Nature Genetics. 2007 Feb;39(2):165–7.  
 64 
258. Véron A, Blein S, Cox DG. Genome-wide association studies and the clinic: a 
focus on breast cancer. Biomarkers Med. 2014 Feb;8(2):287–96.  
259. Hindorff LA, MacArthur J, Morales J, Junkins HA, Hall PN, Klemm AK, and 
Manolio TA. A Catalog of Published Genome-Wide Association Studies. 
Available at: www.genome.gov/gwastudies. Accessed [2014-04-25].  
260. Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, Milne RL, et 
al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. 
Nature Publishing Group. 2013 Apr;45(4):353–61–361e1–2.  
261. Antoniou AC, Pharoah PDP, McMullan G, Day NE, Stratton MR, Peto J, et al. A 
comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 
and other genes. Br J Cancer. 2002 Jan 7;86(1):76–83.  
262. Sapkota Y. Germline DNA variations in breast cancer predisposition and 
prognosis: a systematic review of the literature. Cytogenet Genome Res. 
2014;144(2):77–91.  
263. Ghoussaini M, Pharoah PDP. Polygenic susceptibility to breast cancer: current 
state-of-the-art. Future Oncol. 2009 Jun;5(5):689–701.  
264. Fanale D, Amodeo V, Corsini LR, Rizzo S, Bazan V, Russo A. Breast cancer 
genome-wide association studies: there is strength in numbers. Oncogene. 2012 
Apr 26;31(17):2121–8.  
265. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, et al. An expression 
signature for p53 status in human breast cancer predicts mutation status, 
transcriptional effects, and patient survival. Proc Natl Acad Sci USA. 2005 Sep 
20;102(38):13550–5.  
266. Pawitan Y, Bjohle J, Amler L, Borg A-L, Egyhazi S, Hall P, et al. Gene expression 
profiling spares early breast cancer patients from adjuvant therapy: derived and 
validated in two population-based cohorts. Breast Cancer Res. 2005;7(6):R953–64.  
267. Magnusson C, Baron JA, Correia N, Bergström R, Adami HO, Persson I. Breast-
cancer risk following long-term oestrogen- and oestrogen-progestin-replacement 
therapy. Int J Cancer. 1999 May 5;81(3):339–44.  
268. Andersson Y, de Boniface J, Jönsson PE, Ingvar C, Liljegren G, Bergkvist L, et al. 
Axillary recurrence rate 5 years after negative sentinel node biopsy for breast 
cancer. Br J Surg. 2012 Feb;99(2):226–31.  
269. Ma R, Fredriksson I, Karthik G-M, Winn G, Darai-Ramqvist E, Bergh J, et al. 
Superficial scrapings from breast tumors is a source for biobanking and research 
purposes. Laboratory Investigation. 2014 Jul;94(7):796–805.  
270. Ramos-Vara JA. Technical aspects of immunohistochemistry. Vet Pathol. 2005 
Jul;42(4):405–26.  
271. Mighell AJ, Hume WJ, Robinson PA. An overview of the complexities and 
subtleties of immunohistochemistry. Oral Dis. 1998 Sep;4(3):217–23.  
272. Krecsák L, Micsik T, Kiszler G, Krenács T, Szabó D, Jónás V, et al. Technical note 
  65 
on the validation of a semi-automated image analysis software application for 
estrogen and progesterone receptor detection in breast cancer. Diagn Pathol. 
2011;6:6.  
273. Słodkowska J, García-Rojo M. Digital pathology in personalized cancer therapy. 
Stud Health Technol Inform. 2012;179:143–54.  
274. Saiki RK, Scharf S, Faloona F, Mullis KB, Horn GT, Erlich HA, et al. Enzymatic 
amplification of beta-globin genomic sequences and restriction site analysis for 
diagnosis of sickle cell anemia. Science. 1985 Dec 20;230(4732):1350–4.  
275. Mardis ER. Next-generation DNA sequencing methods. Annu Rev Genomics Hum 
Genet. 2008;9:387–402.  
276. Majewski J, Schwartzentruber J, Lalonde E, Montpetit A, Jabado N. What can 
exome sequencing do for you? J Med Genet. 2011 Sep;48(9):580–9.  
277. Ng SB, Turner EH, Robertson PD, Flygare SD, Bigham AW, Lee C, et al. Targeted 
capture and massively parallel sequencing of 12 human exomes. Nature. 2009 Sep 
10;461(7261):272–6.  
278. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler 
transform. Bioinformatics. 2010 Mar 1;26(5):589–95.  
279. Xu H, DiCarlo J, Satya RV, Peng Q, Wang Y. Comparison of somatic mutation 
calling methods in amplicon and whole exome sequence data. BMC Genomics. 
2014;15:244.  
280. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in 
logistic and Cox regression. Am J Epidemiol. 2007 Mar 15;165(6):710–8.  
281. Nixon AJ, Neuberg D, Hayes DF, Gelman R, Connolly JL, Schnitt S, et al. 
Relationship of patient age to pathologic features of the tumor and prognosis for 
patients with stage I or II breast cancer. J Clin Oncol. 1994 May;12(5):888–94.  
282. Ding S-L, Sheu L-F, Yu J-C, Yang T-L, Chen B, Leu F-J, et al. Expression of 
estrogen receptor-alpha and Ki67 in relation to pathological and molecular features 
in early-onset infiltrating ductal carcinoma. J Biomed Sci. 2004 Nov;11(6):911–9.  
283. Carder PJ, Murphy CE, Dervan P, Kennedy M, McCann A, Saunders PTK, et al. A 
Multi-Centre Investigation Towards Reaching a Consensus on the 
Immunohistochemical Detection of ERβ in Archival Formalin-ﬁxed Paraffin 
Embedded Human Breast Tissue. Breast Cancer Res Treat. 2005 Aug;92(3):287–
93.  
284. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao 
J, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell. 2007 
Mar;11(3):259–73.  
285. Dave B, Mittal V, Tan NM, Chang JC. Epithelial-mesenchymal transition, cancer 
stem cells and treatment resistance. Breast Cancer Res. 2012;14(1):202.  
286. Tomasetti C, Vogelstein B. Cancer etiology. Variation in cancer risk among tissues 
can be explained by the number of stem cell divisions. Science. 2015 Jan 
 66 
2;347(6217):78–81.  
287. Lindström LS, Karlsson E, Wilking UM, Johansson U, Hartman J, Lidbrink EK, et 
al. Clinically used breast cancer markers such as estrogen receptor, progesterone 
receptor, and human epidermal growth factor receptor 2 are unstable throughout 
tumor progression. Journal of Clinical Oncology. 2012 Jul 20;30(21):2601–8.  
 
